



A Symbol of Excellence

---

## ICON LIFECYCLE SCIENCES PUBLICATIONS – 2009

---

### **Cardiovascular**

Fonarow GC, French W J, **Frederick PD**. *Trends in the use of lipid-lowering medications at discharge in patients with acute myocardial infarction: 1998 to 2006*. Am Heart J. 2009. 157:185-194 e2

Spalding J, **Exuzides A, Colby C, Neil NN, Noe LL**. *Inpatient resource use among patients treated for primary atrial fibrillation (AF): role of clinical factors and choice of initial conversion therapy*. The International Society for Pharmacoeconomics and Outcomes Research 14th Annual International Meeting. 2009.

Spalding J, **Neil NN, Exuzides A, Colby C, Noe LL**. *Management of primary atrial fibrillation (AF): patient characteristics and hospital care setting*. The International Society for Pharmacoeconomics and Outcomes Research 14th Annual International Meeting. 2009.

Nagaraj H, Mayhew M, **Frederick PD**, Rogers W J, Misra V. *Differential treatments in patients with systemic lupus erythematosus or rheumatoid arthritis hospitalized with myocardial infarction: A NRM Data Analysis*. American College of Cardiology 58th Annual Scientific Session. 2009.

### **Diagnostics/Radiology**

Main M, **Exuzides A, Colby C**, Feinstein S, Goldman J, Waaler A, Grayburn P. *Optison™ Does Not Increase Mortality in Critically Ill Patients: Preliminary Results from a Retrospective Matched Case-Control Study*. American College of Cardiology. 2009.

### **Hematology**

Popova EY, Krauss SW, **Short SA**, Lee G, Villalobos J, Ezzell J. *Chromatin condensation in terminally differentiating mouse erythroblasts does not involve special architectural proteins but depends on histone deacetylation*. Chromosome research. 2009. 17(1):47-64

Naiem A, Friedman L, Whitlock KB, **Lubeck DP**, Glaspy J. *Patterns of care in community-based oncology practices for anemia associated with myelosuppressive chemotherapy*. J Oncol Practice. 2009. In press

### **Infectious Disease/Immunology**

Butler LM, Osmond DH, **Jones AG**, Martin JN. *Use of saliva as a lubricant in anal sexual practices among homosexual men*. JAIDS. 2009. 50:162-7

### **Nephrology**

**Neil NN**, Walker DR, Sesso R, Blackburn JC, Tschosik EA, Sciaraffia V, Garcia-Contreras F, Capsa D, Bhattacharyya SK. *Gaining Efficiencies: Resources and Demand for Dialysis around the Globe*. Value Health. 2009.

---

ICON Clinical Research  
Lifecycle Sciences Group  
(415) 741-2101

[Deborah.Lubeck@iconplc.com](mailto:Deborah.Lubeck@iconplc.com)



---

**Neil NN**, Guest S, Wong L, Inglese G, Bhattacharyya S, Gehr T, Walker DR, Golper T. *The financial implications for Medicare of greater use of peritoneal dialysis*. Clin Ther 2009;31:880-888.

### **Respiratory/Pulmonary**

Sawicki GS, **Rasouliyan L**, Ren CL. *The Impact of MRSA on Lung Function in Patients with Cystic Fibrosis*. American Journal of Respiratory and Critical Care Medicine. 2009. 179:734-5

**Miller DP**, Tom G, **Rasouliyan L**, Chipps B. *Patient-Reported Outcomes among Omalizumab and Salmeterol/Fluticasone Combination Therapy Patients*. Journal of Asthma. 2009. 46:179-85

Haselkorn T, Fish J E, Zeiger R, Szeffler S, **Miller DP**, Chipps B. *Asthma control and risk of future asthma exacerbations: Evaluation of the impairment domain of the NHLBI guidelines in the TENOR cohort*. American Academy of Asthma, Allergy and Immunology. 2009. No

Krichman A, **Turner MP**, Wason P, **Graves Jones AM**, McGoon MD, Farber H. *REVEAL Registry: Comparison of Adult Patients With and Without Comorbid Medical Conditions*. The International Society for Heart & Lung Transplantation. 2009.

Farber H, McGoon MD, Benza R L, Wason P, **Miller DP**, Badesch D B. *REVEAL Registry: Implications and Outcomes of Functional Class and Hemodynamics on Patients With PAH*. The International Society for Heart & Lung Transplantation. 2009.

Frost AE, Barst R, Elliott CG, Farber H, McGoon MD, **Miller DP**. *REVEAL Registry: Prevalence, demographics and outcomes in patients with pulmonary arterial hypertension (PAH) characterized by higher left sided pressures*. The International Society for Heart & Lung Transplantation. 2009.

Barst RJ, Ivy D, Badesch DB, Benza RL, Elliott CG, Farber HW, Frost AE, Krichman A, Liou TG, Raskob GE, Wason P, Feldkircher K, **Foreman AJ**. *REVEAL Registry: Comparison of Patients with Childhood-Onset and Adult-Onset Idiopathic Pulmonary Arterial Hypertension*. International Society for Heart and Lung Transplantation: 29th Annual Meeting & Scientific Sessions. 2009.

Barst RJ, Ivy D, Badesch DB, Benza RL, Elliott CG, Farber HW, Frost AE, Krichman A, Liou TG, Raskob GE, Wason P, Feldkircher K, **Foreman AJ**. *REVEAL Registry: Pediatric IPAH Versus Pediatric Pulmonary Vascular Disease Associated with Congenital Heart Disease*. The International Society for Heart and Lung Transplantation: 29th Annual Meeting & Scientific Sessions. 2009.

### **Urology**

**Cisternas MG**, **Foreman AJ**, Marshall TS, Runken MC, Kobashi KC, Seifeldin R. *Estimating the prevalence and economic burden of overactive bladder among Medicare beneficiaries prior to Medicare Part D coverage*. Current Medical Research and Opinion. 2009. 25:911-919

### **Methodologic**

**Pless R**. *EDC Project Success*. Applied Clinical Trials. 2009. Vol 18, #4:56-64



A Symbol of Excellence

---

## ICON LIFECYCLE SCIENCES PUBLICATIONS – 2008

---

### **Cardiovascular**

Spalding J, **Exuzides A, Adams S, Colby C, Noe LL**. *Inpatient Resource Use Associated with the Treatment of Secondary Atrial Fibrillation*. ISPOR 11th Annual European Congress. 2008.

Steinberg BA, French WJ, Peterson E, **Frederick PD**, Cannon CP. *Is coding for myocardial infarction more accurate now that coding descriptions have been clarified to distinguish ST-elevation myocardial infarction from non-ST elevation myocardial infarction?* Am J Cardiol. 2008. 102:513-7

Belz MK, Spalding J, **Exuzides A, Adams S, Colby C**. *Primary atrial fibrillation: Adverse event-attributable inpatient costs by choice of treatment*. 2008 ACCP Spring Practice and Research Forum. 2008.

Belz MK, Spalding J, **Exuzides A, Adams S, Colby C**. *Primary atrial fibrillation: Inpatient resource use associated with choice of initial acute conversion therapy*. 2008 ACCP Spring Practice and Research Forum. 2008.

Belz M, Spalding J, **Exuzides A, Adams S, Colby C, Noe LL, Neil NN**. *Likelihood and Cost of Adverse Events in Atrial Fibrillation are Associated with Choice of Acute Conversion Therapy*. ISPOR 13th Annual International Meeting. 2008.

Belz M, Spalding J, **Exuzides A, Adams S, Colby C, Neil NN, Noe LL**. *Likelihood of Adverse Events by Initial Acute Conversion Therapy Received Among Atrial Fibrillation Patients*. 9th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke. 2008.

Peterson ED, Shah BR, **Parsons L**, Pollack CV Jr, French WJ, Canto JG, Gibson CM, Rogers WJ. *Trends in quality of care for patients with acute myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006*. Am Heart J. 2008. 156:1045-55

Rogers WJ, **Frederick PD**, Stoehr E, Canto JG, Ornato JP, Gibson CM, Pollack CV Jr, Gore JM, Chandra-Strobos N, Peterson ED, French WJ. *Trends in presenting characteristics and hospital mortality among patients with ST elevation and non-ST elevation myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006*. Am Heart J. 2008. 156:1026-34

Gibson CM, Pride YB, **Frederick PD**, Pollack CV Jr, Canto JG, Tiefenbrunn AJ, Weaver WD, Lambrew CT, French WJ, Peterson ED, Rogers WJ. *Trends in reperfusion strategies, door-to-needle and door-to-balloon times, and in-hospital mortality among patients with ST-segment elevation myocardial infarction enrolled in the National Registry of Myocardial Infarction from 1990 to 2006*. Am Heart J. 2008. 156:1035-44

### **Hematology**

Hornberger J, Reyes C, **Lubeck DP**, Valente N. *Economic evaluation of rituximab plus CVP for advanced follicular lymphoma*. Leuk Lymphoma. 2008. 49:227-36



---

Hornberger J, Reyes C, **Lubeck DP**, Valente N. *Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma*. *Leuk Lymphoma*. 2008. 49:227-36

Zilberberg MD, **Exuzides A**, Spalding J, **Foreman A**, **Jones A G**, Shorr AF. *Clinical outcomes, ICU utilization and costs among hyponatremic ICU patients*. SCCM's 37th Critical Care Congress (Society of Critical Care Medicine). 2008.

Zilberberg MD, **Exuzides A**, Spalding J, **Foreman A**, **Jones A G**, Shorr AF. *Epidemiology, clinical and economic outcomes in a cohort of hyponatremic hospitalized patients*. SCCM's 37th Critical Care Congress (Society of Critical Care Medicine). 2008.

Zilberberg MD, **Exuzides A**, Spalding J, **Foreman A**, **Jones A G**, Shorr AF. *Hyponatremia, mechanical ventilation (MV), ICU and hospital outcomes among patients with pneumonia*. SCCM's 37th Critical Care Congress (Society of Critical Care Medicine). 2008.

Zilberberg MD, **Exuzides A**, Spalding J, **Foreman A**, **Jones A G**, Shorr AF. *Impact of rate of hyponatremia correction on hospital costs and length of stay*. SCCM's 37th Critical Care Congress (Society of Critical Care Medicine). 2008.

Zilberberg MD, **Exuzides A**, Spalding J, **Foreman A**, **Jones A G**, **Colby C**, Shorr AF. *Epidemiology, clinical and economic outcomes of admission hyponatremia among hospitalized patients*. *Curr Med Res Opin*. 2008. 24:1601-1608

Zilberberg MD, **Exuzides A**, Spalding J, **Foreman A**, **Jones A G**, **Colby C**, Shorr AF. *Hyponatremia and hospital outcomes among patients with pneumonia: a retrospective cohort study*. *BMC Pulm Med*. 2008. 8:16

**Mathias SD**, Gao SK, **Miller K**, Cella D, Snyder C, Turner R, Wu A, Bussel JB, George JN, McMillan R, Wysocki D K, Nichol JL. *Impact of chronic Immune Thrombocytopenic Purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective*. *Health Qual Life Outcomes*. 2008. 6:13

### ***Infectious Disease/Immunology***

Phillips AM, **Graves Jones AM**, Osmond DH, Pollack LM, Catania JA, Martin JN. *Awareness of Kaposi's Sarcoma-Associated Herpesvirus among men who have sex with men*. *Sex Transm Dis*. 2008. 35:1011-4

Hsue PY, Deeks SG, Farah HH, Palav S, Ahmed SY, Schnell A, **Ellman AB**. *Role of HIV and human herpesvirus-8 infection in pulmonary arterial hypertension*. *AIDS*. 2008. 23:825-33

### ***Nephrology***

Just PM, Riella MC, Tschosik EA, **Noe LL**, Bhattacharyya SK, de Charro F. *Economic evaluations of dialysis treatment modalities*. *Health Policy*. 2008. 86:163-80



---

Just PM, de Charro FT, Tschosik EA, **Noe LL**, Bhattacharyya SK, Riella M C. *Reimbursement and economic factors influencing dialysis modality choice around the world*. Nephrol Dial Transplant. 2008. 23:2365-73

## **Oncology**

Ramsey SD, Martins RG, Blough DK, **Lubeck DP**. *Second-line and third-line chemotherapy for lung cancer: use and cost*. Am J Manag Care. 2008. 14:297-306

Danese MD, Reyes C, Northridge K, **Lubeck DP**, Lin C Y, O'Connor P. *Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer*. Clin Ther. 2008. 30:775-84

Carlson JJ, Reyes C, Oestreicher N, **Lubeck DP**, Ramsey SD, Veenstra DL. *Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC)*. Lung Cancer. 2008. 61:405-15

Shah JB, McKiernan JM, **Elkin EP**, Carroll PR, Meng MV, CaPSURE Investigators. *Prostate biopsy patterns in the CaPSURE database: Evolution with time and impact on outcome after prostatectomy*. Journal of Urology. 2008. 179:136-140

Sadetsky N, **Elkin EP**, Latini DM, DuChane J, Carroll PR, CaPSURE Investigators. *Prostate cancer outcomes among older men: Insurance status comparisons results from CaPSURE database*. Prostate Cancer and Prostatic Diseases. 2008. 11:280-287

Ramsey SD, Martins RG, Blough DK, Tock LS, **Lubeck DP**, Reyes CM. *Second-line and third-line chemotherapy for lung cancer: use and cost*. Am J Manag Care. 2008. 14:297-306

Henry DH, Viswanathan HN, **Elkin EP**, Traina S, Wade S, Cella D. *Symptoms and treatment burden associated with cancer treatment: Results from a cross-sectional national survey in the U.S*. Supportive Care in Cancer. 2008. 16:791-801

Cella D, Viswanathan HN, Hays RD, Mendoza TR, Stein KD, **Pasta DJ**, **Foreman A**, Vadhan-Raj S, Kallich JD. *Development of a fatigue and functional impact scale in anemic cancer patients receiving chemotherapy*. Cancer. 2008. 113:1480-8

## **Psychiatry**

Lyubomirsky S, **Dickerhoof R**. *A construal approach to increasing happiness*. *Social psychological foundations of clinical psychology*, New York, NY: Guilford Publications,. 2008. in press

Darby JK, **Pasta DJ**, Wilson MG, Herbert J. *Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study*. Clin Drug Investig. 2008. 28:553-64



---

## **Respiratory/Pulmonary**

**Rasouliyan L, Miller DP.** *The Logic and Logistics of Logistic Regression.* Pharmaceutical Industry SAS Users Group. 2008.

Jones C A, Hubert C, Haselkorn T, **Miller DP**, Peters S P, Weiss S T. *Relationship between Asthma Control and Activity Limitation: Insights from the REACT Study.* Annual Meeting of the American Academy of Allergy, Asthma, and Immunology. 2008.

Ren CL, **Pasta DJ, Rasouliyan L**, Wagener J S, Konstan M W, Morgan W J. *Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis.* J Pediatr. 2008. 153:746-51

Sawicki G S, **Rasouliyan L, Pasta DJ**, Regelman W E, Wagener J S, Waltz D A, Ren C L. *The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis.* Pediatr Pulmonol. 2008. 43:1117-23

Campbell J D, Borish L, Haselkorn T, **Rasouliyan L**, Lee J H, Wenzel S E, Sullivan S D. *The response to combination therapy treatment regimens in severe/difficult-to-treat asthma.* Eur Respir J. 2008. 32:1237-42

VanDevanter D R, **Rasouliyan L**, Murphy T M, Morgan W J, Ren C L, Konstan M W, Wagener J S. *Trends in the clinical characteristics of the US cystic fibrosis patient population from 1995 to 2005.* Pediatr Pulmonol. 2008. 43:739-44

Kim J J, Huen K, **Adams S**, Smorodinsky S, Hoats A, Malig B, Lipsett M, Ostro B. *Residential traffic and children's respiratory health.* Environmental Health Perspectives. 2008. 116:1274-9

Moskowitz S M, **Silva SJ**, Mayer-Hamblett N, **Pasta DJ, Mink DR**, Mabie J A, Konstan M W, Wagener J S. *Shifting patterns of inhaled antibiotic use in cystic fibrosis.* Pediatr Pulmonol. 2008. 43:874-81

Moskowitz S M, **Silva SJ**, Mayer-Hamblett N, **Pasta DJ, Mink DR**, Mabie J A, Konstan M W, Wagener J S. *Shifting patterns of inhaled antibiotic use in cystic fibrosis.* Pediatr Pulmonol. 2008. 43:874-81

Donohue J F, Hanania N A, Ciubotaru R L, **Noe LL, Pasta DJ**, Schaefer K, Claus R, Andrews W T, Roach J. *Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: A 2-week, multicenter, randomized, open-label study.* Clin Ther. 2008. 30:989-1002

## **Rheumatology/Arthritis**

**Cisternas MG**, Murphy L, Yelin E, **Foreman A, Pasta DJ**, Helmick C. *Trends in Medical Care Expenditures for Persons with Arthritis and Other Rheumatic Conditions.* ACR/ARHP Annual Scientific Meeting. 2008.

## **Urology**

Sadetsky N, **Lubeck DP, Pasta DJ**, Latini DM. *Insurance and quality of life in men with prostate cancer: data from the Cancer of the Prostate Strategic Urologic Research Endeavor.* BJU In. 2008. 101:691-697



A Symbol of Excellence

---

Danese M, Reyes C, Lin C, O'Connor P, **Lubeck DP**. *Budget impact of erlotinib for the treatment of locally advanced, unresectable pancreatic cancer*. *Clinical Therapeutics*. 2008. 30:775-784

Zinner N, **Noe LL**, **Rasouliyan L**, Marshall T, Seifeldin R. *Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER*. *Curr Med Res Opin*. 2008. 24:1583-1591

Sadetsky N, **Lubeck DP**, **Pasta DJ**, Latini D M, DuChane J, Carroll P R. *Insurance and quality of life in men with prostate cancer: data from the Cancer of the Prostate Strategic Urological Research Endeavor*. *BJU Int*. 2008. 101:691-7

Arredondo SA, Downs TM, **Lubeck DP**, **Pasta DJ**, **Silva SJ**, Wallace KL, Carroll PR. *Watchful waiting and health related quality of life for patients with localized prostate cancer*. Data From CaPSURE. *J Urol*. 2008. 179:S14-8

### **Methodologic**

**Exuzides A**, **Colby C**, Spalding J. *Estimating Cost-of-Illness Using Generalized Linear Models: An Alternative to the Smearing Approach*. ISPOR 11th Annual European Congress. 2008.

**Pless R**. *An Introduction to Regular Expressions with Examples from Clinical Data*. Northern IL SAS Users Group. 2008.

**Parsons L**. *Creating a Custom Table of Contents in RTF Documents*. Proceedings of the SAS Global Forum - 2008 Conference. 2008.

**Pless R**. *Data on Demand with Enterprise Guide: A Cheap and Easy Approach to Real-time Database Access*. Northern IL SAS Users Group. 2008.

**Foreman AJ**, **Lai GP**, **Miller DP**. *Surviving Left Truncation Using PROC PHREG*. 2008 Annual Conference: Western Users of SAS Software. 2008.

Blanchette C, Kamble K, **Exuzides A**, Gibbons C. *Use of Real World Data: Challenges in the Analysis of Patient Registry Data*. Proceeding of the ISPOR 11th Annual European Congress. 2008. Nov 8-11: Athens, Greece.



---

## ICON LIFECYCLE SCIENCES PUBLICATIONS – 2007

---

### **Autoimmune Disease**

Bennett R, Cisternas MG, Foreman AJ, Miller DP, AL-Sabbagh A. *Impact of relapses on total cost of care for patients with Multiple Sclerosis*. Twelfth Annual International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Meeting. 2007.

### **Cardiovascular**

Dauerman HL, Frederick PD, Miller DP, French WJ. *Current incidence and clinical outcomes of bivalirudin administration among patients undergoing primary coronary intervention for stent thrombosis elevation acute myocardial infarction*. Coron Artery Dis. 2007. 18:141-8

Nallamotheu BK, Blaney ME, Morris SM, Parsons L, Miller DP, Canto JG, Barron HV, Krumholz HM. *Acute reperfusion therapy in ST-elevation myocardial infarction from 1994-2003*. Am J Med. 2007. 120:693-699

McNamara RL, Herrin J, Wang Y, Curtis JP, Bradley EH, Magid DJ, Rathore SS, Nallamotheu BK, Peterson ED, Blaney ME, Frederick PD, Krumholz HM. *Impact of Delay in Door-to-Needle Time on Mortality in Patients With ST-Segment Elevation Myocardial Infarction*. Am J Cardiol. 2007. 100:1227-32

### **Diagnostics/Radiology**

Heddson B, Ronnow K, Olsson M, Miller DP. *Digital versus screen-film mammography: A retrospective comparison in a population-based screening program*. Eur J Radiol. 2007. 64:419-425

### **Endocrinology/Metabolic**

Patel B, Leslie S, Aranda G, McCoy M, Baran R, Bron M, Xu Y. *Retrospective comparison of compliance to fixed-dose combination versus single agent combination therapy for the treatment of diabetes*. European International Society of Pharmacoeconomics and Outcomes Research Meeting: Dublin, Ireland. 2007.

### **Gastroenterology/Digestive Diseases**

Lichtenstein GR, Cohen RD, Feagan BG, Sandborn WJ, Salzberg BA, Chen DM, Mink DR, Turner MP, Broussard DL, Diamond RH. *Greater Exposure to Infliximab Is Not Associated with Increase in Mortality and Serious Infections - TREAT™ Registry Data with Nearly 20,000 Patient-Years of Follow-Up*. Digestive Disease Week (DDW). 2007.

Lichtenstein GR, Cohen RD, Feagan BG, Sanborn WJ, Salzberg BA, Chen DM, Turner MP, Mink DR, Broussard DL, Diamond RH. *Safety of Infliximab and Other Crohn's Disease Therapies - TREAT™ Registry Data with Nearly 20,000 Patient-Years of Follow-Up*. Digestive Disease Week (DDW). 2007.



---

## **Infectious Disease/Immunology**

**Hansen R**, Seifeldin R, **Noe LL**. *Medication adherence in post-transplant immunosuppression: the economic impact of drug-regimen complexity*. Value Health. 2007. 10:A386

**Hansen R**, Seifeldin R, **Noe LL**. *Medication adherence in chronic disease: issues in posttransplant immunosuppression*. Transplant Proc. 2007. 39:1287-300

## **Nephrology**

Herzog CA, Littrell K, Arko C, **Frederick PD**, Blaney M. *Clinical characteristics of dialysis patients with acute myocardial infarction in the United States: a collaborative project of the United States Renal Data System and the National Registry of Myocardial Infarction*. Circulation. 2007. 116:1465-72

Just PM, Riella MC, Tschosik EA, **Noe LL**, De Charro FT, *Bhattacharyya SK*. *Global Economic Evaluations of Dialysis Treatment Modalities*. ISPOR 10th Annual European Congress. 2007.

## **Neurology/CNS**

Picone MA, **Miller K**, Jewell S, **Raassi C**, McBride J, Nadipelli V. *A prospective, web-based, PRO study of individuals with multiple sclerosis participating in the MS Pathways support program: questionnaire development & study design*. 14th Annual International Meeting of The International Society for Quality of Life Research (ISOQOL). 2007.

Blady D, Schwartz RL, Strutin D, Wilson I, Crivera C, Amatniek J, Zhu Y, MFT R, **Parsons L**, **Cimms TA**, Calderon S, **Verhoff R**. *Safety of Galantamine and Galantamine-Memantine Combination Treatment for Mild to Moderate Alzheimer's Disease*. American Society of Consultant 38th Annual Meeting & Exhibition. 2007.

## **Oncology**

Ryan CJ, **Elkin EP**, Cowan J, Carroll PR. *Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: Data from CaPSURE*. Cancer. 2007. 110:81-86

Hanson G R, Odom E, Borden LS Jr, **Neil NN**, Corman JM. *Post-operative drain output as a predictor of bladder neck contracture following radical prostatectomy*. Int Urol Nephrol. 2007. 40:351-354

Garrison LP, **Lubeck DP**, Lalla D, Paton V, Dueck A, Perez EA. *Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer*. Cancer. 2007. 110:489-98

Litwin MS, Greenfield S, **Elkin EP**, **Lubeck DP**, Broering JM, Kaplan SH. *Assessment of prognosis with the Total Illness Burden Index for prostate cancer: Aiding clinicians in treatment choice*. Cancer. 2007. 109:1777-1783

Naeim A, Friedman L, **Elkin EP**, **Adams S**, Viswanathan H, Kallich J. *Patterns of care in patients with chemotherapy receiving erythropoiesis stimulating agents (ESAs)*. Blood. 2007. 110:964



---

**Hoffman S**, Schellinger KA, Propp JM, McCarthy BJ, Campbell RT, Davis FG. *Seasonal variation in incidence of pediatric medulloblastoma in the United States, 1995-2001*. Neuroepidemiology. 2007. 29:89-95

**Colwell HH, Mathias SD**, Ngo NH, Gitlin M, Lu Z J, Knoop T. *The impact of infusion reactions on oncology patients and clinicians in the inpatient and outpatient practice settings: oncology nurses' perspectives*. J Infus Nurs. 2007. 30:153-60

Elliott SP, Meng MV, **Elkin EP**, McAninch JW, DuChane J, Carroll PR, CaPSURE Investigators. *Incidence of urethral stricture after primary treatment for prostate cancer: Data from CaPSURE*. Journal of Urology. 2007. 178:529-534

Scales CD Jr, Moul JW, Curtis LH, **Elkin EP**, Hughes ME, Carroll PR, CaPSURE Investigators. *Prostate cancer in the Baby Boomer generation: Results from CaPSURE*. Urology. 2007. 70:1162-1167

Wilson LS, Tesoro R, **Elkin EP**, Sadetsky N, Broering JM, Latini DM, DuChane J, Mody RR, Carroll PR. *Cumulative cost pattern comparison of prostate cancer treatments*. Cancer. 2007. 109:518-527

### **Ophthalmology**

**Miller K, Mink DR, Mathias SD**, Walt JG. *Multiple methods to estimate the minimal clinically important difference of the Ocular Surface Disease Index®*. Twelfth Annual International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Meeting. 2007.

### **Other**

Mueller-Ohering EM, Schulte T, **Raassi C**, Pfefferbaum A, Sullivan EV. *MRI evidence for anterior callosal transfer in competitive but not parallel global-local processing in normal aging*. Brain Research. 2007. 1142:189-205

### **Psychiatry**

**Dickerhoof R**. *Expressing optimism versus gratitude: A longitudinal investigation of cognitive strategies to increase well-being*. Dissertation Abstracts International: Section B: The Sciences and Engineering. 2007. 68(6-B):4174

Crivera C, Amatriek J, Zhu Y, Gotta D, **Parsons L, Cimms TA**. *Combination Treatment with Galantamine and Memantine: Safety Data in Patients with Mild to Moderate Alzheimer's Disease*. 11th European Federation of Neurological Societies (EFNS) Congress. 2007.

### **Respiratory/Pulmonary**

Chippis BE, Szeffler SJ, Simons FE, Haselkorn T, **Mink DR**, Deniz Y, Lee JH. *Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma*. J Allergy Clin Immunol. 2007. 119:1156-63



A Symbol of Excellence

---

Miller MK, Lee J H, **Miller DP**, Wenzel S E. *Recent asthma exacerbations: a key predictor of future exacerbations*. Respir Med. 2007. 101:481-9

Sullivan SD, **Rasouliyan L**, Russo PA, Kamath T, Chipps BE. *Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma*. Allergy. 2007. 62:126-33

Chen H, Gould M K, Blanc PD, **Miller DP**, Kamath T V, Lee JH. *Asthma control, severity, and quality of life: quantifying the effect of uncontrolled disease*. J Allergy Clin Immunol. 2007. 120:396-402

Padman R, McColley SA, **Miller DP**, Konstan M W, Morgan WJ, Schechter MS. *Infant care patterns at epidemiologic study of cystic fibrosis sites that achieve superior childhood lung function*. Pediatrics. 2007. 119:e531-537

Claus R, **Noe LL**, **Pasta DJ**, Schaefer K, Andrews W, Roach J. *Pharmacoeconomic outcomes of Levalbuterol and Racemic Albuterol in hospitalized patients requiring nebulization therapy (Polaris)*. Twelfth Annual International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Meeting. 2007.

Peters SP, Jones CA, Haselkorn T, **Mink DR**, Valacer DJ, Weiss ST. *Real-world Evaluation of Asthma Control and Treatment (REACT): findings from a national Web-based survey*. J Allergy Clin Immunol. 2007. 119:1454-61

Lee JH, Haselkorn T, Borish L, **Rasouliyan L**, Chipps BE, Wenzel SE. *Risk Factors Associated With Persistent Airflow Limitation in Severe or Difficult-to-Treat Asthma: Insights From the TENOR Study*. Chest. 2007. 132:1882-9

**Pasta DJ**, **Silva S**, **Noe LL**, Claus R, Schaefer K, Andrews W, Roach J. *Quality-adjusted length of stay analysis of hospitalized patients with asthma or copd treated with Levalbuterol or Rcemic Albuterol*. Twelfth Annual International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Meeting. 2007.

Campbell JD, Borish L, **Rasouliyan L**, Haselkorn T, Lee J, Wenzel S, Sullivan SD. *Relationship between combination therapy treatment regimens and measurements of control in moderate to severe asthma*. Twelfth Annual International Society for Pharmacoeconomics and Outcomes Research (ISPOR). 2007.

Borish L, Campbell J, **Rasouliyan L**, Haselkorn T, Lee JH, Wenzel SE, Sullivan SD. *Widely variant asthma control in a cohort of severe or difficult-to-treat asthmatics treated with difference regimens of inhaled corticosteroids and long-acting  $\beta$ -agonists*. ISPOR 12th Annual International Meeting. 2007.

Sullivan SD, Wenzel SE, Bresnahan B W, Zheng B, Lee JH, **Pritchard M**, Kamath TV, Weiss ST. *Association of control and risk of severe asthma-related events in severe or difficult-to-treat asthma patients*. Allergy. 2007. 62:655-60



---

## **Rheumatology/Arthritis**

Yelin E, Murphy L, **Cisternas MG, Foreman A, Pasta DJ**, Helmick C G. *Medical care expenditures and earnings losses among persons with arthritis and other rheumatic conditions in 2003, and comparisons with 1997*. Arthritis Rheum. 2007. 56:1397-407

Yelin E, **Cisternas MG, Foreman A, Pasta DJ**, Murphy L, Helmick C. *National and state medical expenditures and lost earnings attributable to arthritis and other rheumatic conditions—United States, 2003*. Mortality and Morbidity Weekly Report (MMWR). 2007. 56:4-7

## **Urology**

**Cisternas MG, Foreman AJ, Miller DP**. *Controlling for Comorbidities using variations of the Charlson Comorbidity index on medicare claims data: The case of overactive bladder*. Twelfth Annual International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Meeting. 2007.

Litwin MS, Greenfield S, **Elkin EP, Lubeck DP**. *Assessment of prognosis with the Total Illness Burden Index for Prostate Cancer (TIBI-CaP): aiding clinicians in treatment choice*. Cancer. 2007. 109:1777-83

**Noe LL**, Marshall T, Seifelding R, **Rasouliyan L**, Zinner N. *Impact of solifenacin on health-related quality of life, work productivity, medical resource utilization, and health utility in working-age adults*. American College of Clinical Pharmacy's 2007 Annual Meeting. 2007.

**Noe LL**, Marshall TS, **Rasouliyan L**, Runken MC, Zinner NR. *Impact of solifenacin on quality of life, medical care use, work productivity, and health utility in the elderly*. Twelfth Annual International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Meeting. 2007.

Arredondo SA, Latini D M, Sadetsky N, Kawakami J, **Pasta DJ**, DuChane J, Carroll P R. *Quality of life for men receiving a second treatment for prostate cancer*. J Urol. 2007. 177:273-8: discussion 278-9

## **Methodologic**

**Gordon MJ**. *Patient registry strategies: Why strategy is the cornerstone of success*. Applied Clinical Trials. 2007. 16:66

**Pless R**. *Data on Demand with Enterprise Guide: A Cheap and Easy Approach to Real-time Database Access*. SAS Global Forum. 2007.

**Pless R**. *SAS Tools for Program Automation*. SAS Global Forum. 2007.

**Adams S, Mink DR, Miller DP**. *Recreating the SELECTION=SCORE model specification with the BEST=n Effect Selection option for PROC SURVEYLOGISTIC*. Proceedings of the Western users of SAS Software Fifteenth Annual Conference. 2007.

Jones CA, Haselkorn T, Valacer DJ, **Mink DR**, Peters SP, Weiss ST. *The Influence of Patient Attitudes on Asthma Control: Insights from the REACT Study*. International Conference of the American Thoracic Society. 2007.



---

## ICON LIFECYCLE SCIENCES PUBLICATIONS – 2006

---

### **Anesthesiology/General Surgery**

**Lubeck DP.** Use of observational databases (registries) in research. *Clinical Research Methods for Surgeons*. Humana Press. 2006. 95-104

### **Cardiovascular**

Wiviott SD, Morrow DA, **Frederick PD**, Antman EM, Braunwald E. *Application of the Thrombolysis in Myocardial Infarction risk index in non-ST-segment elevation myocardial infarction: evaluation of patients in the National Registry of Myocardial Infarction*. J Am Coll Cardiol. 2006. 47:1553-8

Bromberg-Marin G, Marin-Neto JA, **Parsons LS**, Canto JG, Rogers WJ. *Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4)*. Am J Cardiol. 2006. 98:1125-31

Steinberg BA, French WJ, Peterson ED, **Frederick PD**, Cannon CP. *Missed Diagnosis of the Diagnosis Codes: Comparison of International Classification of Diseases, 9th Revision Coding and ST- Versus Non-ST-Elevation Myocardial Infarction Diagnosis in the National Registry of Myocardial Infarction*. Crit Pathw Cardiol. 2006. 5:59-63

Van de Graaff E, Dutta M, Das P, Shry EA, **Frederick PD**, Blaney M, **Pasta DJ**, Steinhubl S R. *Early coronary revascularization diminishes the risk of ischemic stroke with acute myocardial infarction*. Stroke. 2006. 37:2546-51

McNamara RL, Wang Y, Herrin J, Curtis JP, Bradley EH, Magid DJ, Peterson ED, Blaney M, **Frederick PD**, Krumholz HM. *Effect of door-to-balloon time on mortality in patients with ST-segment elevation myocardial infarction*. J Am Coll Cardiol. 2006. 47:2180-6

Pinto DS, Kirtane AJ, Nallamothu BK, Murphy SA, Cohen DJ, Laham RJ, Cutlip DE, Bates ER, **Frederick PD**, **Miller DP**, Carrozza JP Jr, Antman EM, Cannon CP, Gibson CM. *Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy*. Circulation. 2006. 114:2019-25

### **Diagnostics/Radiology**

Raffy P, Gaudeau Y, **Miller DP**, Moureaux JM, Castellino RA. *Computer-aided detection of solid lung nodules in lossy compressed multidetector computed tomography chest exams*. Acad Radiol. 2006. 13:1194-203



A Symbol of Excellence

---

### **Endocrinology/Metabolic**

Baker V L, Rone H M, **Pasta DJ**, Nelson H P, Gvakharia M, Adamson G D. *Correlation of thyroid stimulating hormone (TSH) level with pregnancy outcome in women undergoing in vitro fertilization*. Am J Obstet Gynecol. 2006. 194:1668-74: discussion 1674-5

Gertler P, Simcoe T, **Exuzides A**, Newell D. *The impact of a disease management program for diabetes*. White paper with UC Berkeley. 2006.

### **Gastroenterology/Digestive Diseases**

**Colwell HH**, Hunt BJ, **Pasta DJ**, Palo WA, **Mathias SD**, Joseph-Ridge N. *Gout Assessment Questionnaire: Initial results of reliability, validity and responsiveness*. Int J Clin Pract. 2006. 60:1210-7

Lichtenstein GR, Feagan BG, Cohen RD, Salzberg B A, Diamond R H, **Chen DM**, **Pritchard ML**, Sandborn W J. *Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry*. Clin Gastroenterol Hepatol. 2006. 4:621-30

Lichtenstein GR, Olson A, Travers S, Diamond R H, **Chen DM**, **Pritchard ML**, Feagan B G, Cohen R D, Salzberg B A, Hanauer S B, Sandborn W J. *Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease*. Am J Gastroenterol. 2006. 101:1030-8

### **Hematology**

Combs S, **Neil NN**, Aboulaflia D M. *Liposomal doxorubicin, cyclophosphamide, and etoposide and antiretroviral therapy for patients with AIDS-related lymphoma: a pilot study*. Oncologist. 2006. 11:666-73

Lee G, Lo A, **Short SA**, Mankelov TJ, Spring F, Parsons SF. *Targeted gene deletion demonstrates that the cell adhesion molecule ICAM-4 is critical for erythroblastic island formation*. Blood. 2006. 108(6):2064-71

### **Infectious Disease/Immunology**

Page-Shafer K, Fox, Rusch M, **Ellman A**, Andrews W, Deeks S, Martin J. *Significant hepatitis C infection but no treatment in a well characterized cohort of HIV infected patients*. 2006 Conference on retroviruses and opportunistic infections (CROI) Denver, CO. 2006.

### **Oncology**

Bhattacharyya SK, **Colwell HH**, **Mathias SD**. *Impact of Infusion Reactions on Oncology Patients, Families, and Clinical Staff*. American Psychosocial Oncology Society Third Annual Conference. 2006.

Ramsey SD, Clarke L, Kamath TV, **Lubeck DP**. *Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a US health insurance plan*. JMCP. 2006. 12:472-78

Meng MV, **Elkin EP**, DuChane J, Carroll PR. *Impact of increased number of biopsies on the nature of prostate cancer identified*. Journal of Urology. 2006. 176:63-68

---

ICON Clinical Research  
Lifecycle Sciences Group  
(415) 741-2101

[Deborah.Lubeck@iconplc.com](mailto:Deborah.Lubeck@iconplc.com)



---

**Colwell HH, Pritchard M, Mathias SD, Lu ZJ, Wright N.** *Psychometric Evaluation of a Patient Reported Outcome Questionnaire for Metastatic Colorectal Cancer.* International Society of Pharmacoeconomics and Outcomes Research 9th Annual European Congress. 2006.

Ryan CJ, **Elkin EP**, Small EJ, DuChane J, Carroll PR. *Reduced incidence of bony metastasis at initial prostate cancer diagnosis: Data from CAPSURE.* Urologic Oncology. 2006. 24:396-402

Hu JC, **Elkin EP**, Krupski TL, Gore J, Litwin MS. *The effect of postprostatectomy external beam radiotherapy on quality of life: Results from the Cancer of the Prostate Strategic Urologic research Endeavor.* Cancer. 2006. 107:281-288

Kawakami J, Cowan JE, **Elkin EP**, Latini DM, DuChane J, Carroll PR. *Androgen-deprivation therapy as primary treatment for localized prostate cancer: Data from Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE).* Cancer. 2006. 106:1708-1714

Marr PL, **Elkin EP**, Arredondo SA, Broering JM, DuChane J, Carroll PR. *Comorbidity and primary treatment for localized prostate cancer: Data from CaPSURE.* Journal of Urology. 2006. 175:1326-1331

Latini DM, **Elkin EP**, Cooperberg MR, Sadetsky N, DuChane J, Carroll PR. *Differences in clinical characteristics and disease-free survival for Latino African American, and non-Latino white men with localized prostate cancer: Results from CaPSURE.* Cancer. 2006. 106:789-795

Greene K, **Elkin EP**, Karapetian A, DuChane J, Carroll PR, Kane CJ, CaPSURE Investigators. *Prostate biopsy tumor extent but not location predicts recurrence after radical prostatectomy: Results from CaPSURE.* Journal of Urology. 2006. 175:125-129

Taga M, Yamauchi K, **Odle J**, Furian L, Sundaresan A, Pellis NR, Andrassy RJ, Kulkarni AD. *Melanoma Growth and Tumorigenicity in Models of Microgravity.* Aviation, Space and Environmental Medicine (ASEM) Journal. 2006. 77:1113-1116

Arredondo SA, **Elkin EP**, Marr PL, Latini DM, DuChane J, Litwin MS, Carroll PR, CaPSURE Investigators. *The impact of comorbidity on health-related quality of life in men undergoing radical prostatectomy: Data from CapSURE.* Urology. 2006. 67:559-565

Cooperberg MR, Freedland SJ, **Pasta DJ, Elkin EP**, Presti JC Jr, Amling CL, Terris MK, Aronson WJ, Kane CJ, Carroll PR. *Multi-institutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy.* Cancer. 2006. 107:2384-2391

## **Psychiatry**

Lyubomirsky S, **Dickerhoof R.** *A construal approach to increasing happiness.* J.E. Maddux and J.P. Tangney (Eds). Social psychological foundations of clinical psychology, New York, NY: Guilford Publications. 2006. 160-178

Lyubomirsky S, Sousa L, **Dickerhoof R.** *The medium is the message: The costs and benefits of writing, talking, and thinking about life's triumphs and defeats.* Journal of Personality and Social Psychology,. 2006. 692-708



---

## **Respiratory/Pulmonary**

Haselkorn T, Lee JH, **Miller DP**, Weiss ST. *Racial disparities in asthma-related health outcomes in TENOR*. American Thoracic Society. 2006.

Chen H, **Miller DP**, Hayden ML, Blanc PD, Lee JH. Can patients with mild asthma be “difficult to treat”? American Thoracic Society. 2006. No

Haselkorn T, Borish L, **Miller DP**, Weiss ST, Wong DA. *High prevalence of skin test positivity in severe or difficult-to-treat asthma*. J Asthma. 2006. 43:745-752

Lee JH, Haselkorn T, Chipps BE, **Miller DP**, Wenzel S E, Tenor Study G. *Gender differences in IgE-mediated allergic asthma in the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study*. J Asthma. 2006. 43:179-184

McMullen AH, **Pasta DJ**, **Frederick PD**, Konstan MW, Morgan WJ, Schechter MS, Wagener JS. *Impact of pregnancy on women with cystic fibrosis*. Chest. 2006. 129:706-11

Borish L, Campbell J, **Rasouliyan L**, Haselkorn T, Lee JH, Wenzel SE, Sullivan SD. *Widely variant asthma control in a cohort of severe or difficult-to-treat asthmatics treated with difference regimens of inhaled corticosteroids and long-acting  $\beta$ -agonists*. The Annual Meeting of the American College of Allergy, Asthma & Immunology. 2006.

Miller MK, Lee JH, Blanc PD, **Pasta DJ**, Gujrathi S, Barron H, Wenzel SE, Weiss ST. *TENOR risk score predicts healthcare in adults with severe or difficult-to-treat asthma*. Eur Respir J. 2006. 28:1145-55

## **Rheumatology/Arthritis**

Chiou CF, Sherbourne CD, Cornelio I, **Lubeck DP**. *Revalidation of the original Cedars-Sinai health-related quality of life in rheumatoid arthritis questionnaire*. J Rheumatol. 2006. 33:256-62

Chiou CF, Sherbourne CD, Cornelio I, **Lubeck DP**, Paulus HE. *Development and validation of the revised Cedars-Sinai health-related quality of life for rheumatoid arthritis instrument*. Arthritis Rheum. 2006. 55:856-863

## **Urology**

Schoen EJ, **Colby C**, To TT. *Cost analysis of neonatal circumcision in a large health maintenance organization*. J Urol. 2006. 175:1111-5

Panjabi SS, **Neil NN**, **Ogden KO**, Black LK, Seifeldin R. *Cost Effectiveness of Alternative Treatments for Overactive Bladder*. Academy of Managed Care Pharmacy, 2006 Educational Conference. 2006.

Cooperberg M R, Freedland S J, **Pasta DJ**, **Elkin EP**, Presti J C Jr, Amling C L, Terris M K, Aronson W J, Kane C J, Carroll P R. *Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy*. Cancer. 2006. 107:2384-91



---

## **Women's Health**

**Mathias SD, Colwell HH, Lococo J M, Karvois D L, Pritchard ML, Friedman A J.** *ORTHO birth control satisfaction assessment tool: assessing sensitivity to change and predictors of satisfaction.* Contraception. 2006. 74:303-8

**Colwell HH, Mathias SD, Cimms TA, Rothman M, Friedman A J, Patrick D L.** *The ORTHO BC-SAT--a satisfaction questionnaire for women using hormonal contraceptives.* Qual Life Res. 2006. 15:1621-31

## **Methodologic**

**Antonini R.** *CLR Made Clear.* SQL Server Standard. 2006. 24-27

**Parsons L.** *Enhancing RTF Output with RTF Control Words and In-Line Formatting.* Proceedings of the 2006 Pharmaceutical Industry SAS Users Group Conference. 2006. P004

**Antonini R.** *Implementing Data Audit Trails in SQL Server (Part One).* SQL Server Standard. 2006. 40003

**Pless R.** *Meta-data That You (Probably) Didn't Know You Had: An Introduction to SAS Dictionaries and Automatic Macro Variables.* Northern IL SAS Users Group. 2006.

**Pless R.** *Meta-data That You (Probably) Didn't Know You Had: An Introduction to SAS Dictionaries and Automatic Macro Variables.* Windy City SAS Users Group. 2006.

**Pless R.** *Meta-data That You (Probably) Didn't Know You Had: An Introduction to SAS Dictionaries and Automatic Macro Variables.* Pharmaceutical SAS Users Group. 2006.

**Foreman A, Cisternas MG.** *Easy Methods to Investigate Large Datasets Using ODS Graphics and New Features in SAS 9.* Fourteenth Annual Western Users of SAS® Software Regional Users Group Conference. 2006.

Spetz J, **Adams S.** *How can employment-based benefits help the nurse shortage?* Health Affairs. 2006. 25:212-8

**Mink DR, Pasta DJ.** *Improving Your Graphics Using SAS/GRAPH® Annotate Facility.* Sas Users Group International. 2006.

Shah S, **Pless R.** *Source Code Control with Visual Source Safe.* SQL Server Magazine. 2006.

**Pless R, Antonini R.** *When LIKE Isn't Enough: Learning to Love Regular Expressions.* SQL Server Standard. 2006. 28-30



---

## ICON LIFECYCLE SCIENCES PUBLICATIONS – 2005

---

### **Cardiovascular**

**Parsons LS.** *Using SAS9 ODS Features to Present Table and Graph Data in an Adobe PDF File.* Thirtieth Annual SAS Users Group International (SUGI) Conference. 2005.

Volpp K G, Konetzka R T, Zhu J, **Parsons L**, Peterson E. *Effect of cuts in Medicare reimbursement on process and outcome of care for acute myocardial infarction patients.* Circulation. 2005. 112:2268-75.

Rathore SS, **Frederick PD**, Every N R, Barron H V, Krumholz H M. *Racial differences in reperfusion therapy use in patients hospitalized with myocardial infarction: a regional phenomenon.* Am Heart J. 2005. 149:1074-81.

Spencer F A, **Frederick PD**, Goldberg R J, Gore J M, Tiefenbrunn A J. *Use of combination evidence-based medical therapy prior to acute myocardial infarction (from the National Registry of Myocardial Infarction-4).* Am J Cardiol. 2005. 96:922-6.

Shavelle DM, Rasouli ML, **Frederick P**, Gibson CM, French WJ, *National Registry of Myocardial Infarction Investigators.* *Outcome in patients transferred for percutaneous coronary intervention (a national registry of myocardial infarction 2/3/4 analysis).* Am J Cardiol. 2005. 96:1227-32.

Pitta S R, Grzybowski M, Welch R D, **Frederick PD**, , Wahl R, Zalenski R J. *ST-segment depression on the initial electrocardiogram in acute myocardial infarction-prognostic significance and its effect on short-term mortality: A report from the National Registry of Myocardial Infarction (NRM1-2, 3, 4).* Am J Cardiol. 2005. 95:843-8.

Babaev A, **Frederick PD**, **Pasta DJ**, Every N, Sichrovsky T, Hochman J S. *Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock.* JAMA. 2005. 294:448-54.

Roe M T, **Parsons LS**, Pollack C V Jr, Canto J G, Barron H V, Every N R, Rogers W J, Peterson E D. *Quality of care by classification of myocardial infarction: treatment patterns for ST-segment elevation vs non-ST-segment elevation myocardial infarction.* Arch Intern Med. 2005. 165:1630-6.

Wright RS, Murphy JG, **Frederick PD**, Jaffe AS, French WJ, Mayo Clinic, Rochester MN, Harbor UCLA Medical Center, Los Angeles CA. *Obesity is associated with reduced mortality and complication rates in ST-Elevation myocardial infarction: Results from the National Registry for Myocardial Infarction 4.* Fifty-Fourth Annual Scientific Session Conference (ACC). 2005.

Bradley E H, Herrin J, Mattera J A, Holmboe E S, Wang Y, **Frederick PD**, Roumanis S A, Radford M J, Krumholz H M. *Quality improvement efforts and hospital performance: rates of beta-blocker prescription after acute myocardial infarction.* Med Care. 2005. 43:282-92.

Vaccarino V, Rathore S S, Wenger N K, **Frederick PD**, Abramson J L, Barron H V, Manhapra A, Mallik S, Krumholz H M. *Sex and racial differences in the management of acute myocardial infarction, 1994 through 2002.* N Engl J Med. 2005. 353:671-82.



---

McNamara RL, Wang Y, Herrin J, Curtis J, Bradley E, Magid D, Peterson E, Blaney M, **Frederick PD**, Krumholz H, Yale University New Haven C T. *Does Time From Symptom Onset to Hospital Presentation Influence Importance of Time From Door-to-Balloon?*. Fifty-Fourth Annual Scientific Session Conference (ACC). 2005.

### **Gastroenterology/Digestive Diseases**

Lichtenstein GR, Cohen DJ, Feagan BG, Sanborn WJ, Salzberg BA, **Chen DM**, **Pritchard M**, Diamond RH. *Safety of Infliximab and Other Crohn's Disease Therapies- Updated TREAT™ Registry Data with Over 10,000 Patient-Years of Follow-Up*. Digestive Disease Week. 2005.

### **Hematology**

Combs SA, **Neil NN**, Aboulafia DM. *Liposomal Doxorubicin, Cyclophosphamide, Etoposide (LACE) and Antiretroviral Therapy (ART) for Patients with AIDS-Related Lymphoma (ARL): A Pilot Study*. Ninth International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies. Basic, Epidemiologic and Clinical Research. 2005.

Krauss SW, Lo A, **Short SA**, Koury MJ, Mohandas N, Chasis JA. *Nuclear substructure reorganization during late-stage erythropoiesis is selective and does not involve caspase cleavage of major nuclear substructural proteins*. Blood. 2005. 106(6):2200-5.

### **Infectious Disease/Immunology**

Hunt PW, Deeks SG, **Graves A**, Sinclair E, Bredt B, Martin JN. *Effect of human herpesvirus 8 and hepatitis C virus co-infection on T cell activation among HIV-infected patients*. 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA. 2005.

Sassoon SA, Rosenbloom MJ, O'Reilly A, **Raassi C**, Jack A, Pfefferbaum A. *Effects of comorbid alcoholism and HIV on visuospatial construction, memory, and organizational strategy*. Guze Symposium on Alcoholism. 2005.

### **Nephrology**

Collins AJ, Kasiske B, Herzog C, Chavers B, Foley R, Gilbertson D, Grimm R, Liu J, Louis T, Manning W, Matas A, McBean M, Murray A, St Peter W, Xue J, Fan Q, Guo H, Li S, Li S, Roberts T, Snyder J, **Frederick P**, et al. *Excerpts from the United States Renal Data System 2004 Annual Data Report: atlas of end-stage renal disease in the United States*. Am J Kidney Dis. 2005. 45(1 Suppl 1):A5-7, S1-280.

### **Nephrology/CNS (Mental Health)**

**Pritchard M**, **Colwell HH**, Johnson L, Strauss M, **Mathias SD**. *Assessing Patient and Clinician Satisfaction with Treatment for Non-Malignant Pain: A Validation Study*. ISOQOL 12th Annual Conference. 2005.



A Symbol of Excellence

---

## **Oncology**

Mitchell JA, Cooperberg MR, **Elkin EP**, **Lubeck DP**, Mehta SS, Kane CJ, Carroll PR. *Ability of two pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: Data from CaPSURE*. Journal of Urology. 2005. 173: 1938-1942.

Park S, Meng MV, **Elkin EP**, Speight JL, DuChane J, Carroll PR. *Androgen deprivation use with external beam radiation for prostate cancer: Results from CaPSURE*. Journal of Urology. 2005, 174 1802-1807.

**Cisternas M**, Mrad R, **Noe LL**, **Miller DP**, **Guyan C**. *Application of an Algorithm for Defining Retrospective Cohorts of Colorectal Cancer (CRC) Patients Treated with Different First-Line Chemotherapy Regimens +/- Bevacizumab to Administrative Claims Data*. ISPOR 8th Annual European Congress. 2005.

**Miller K**, Johnson LL, **Colwell HH**, Bhattacharyya SK, Deeter RG, **Mathias SD**. *Assessing QoL in Patients with Metastatic Colorectal Cancer (MCRC) Treated with Chemotherapy*. International Society for Pharmacoeconomics & Outcomes Research 8th Annual European Congress. 2005.

**Cisternas M**, Mrad R, **Noe LL**, **Miller DP**, **Guyan C**. *Development of an Algorithm for the Identification and Classification of Colorectal Cancer (CRC) Patients According to First-line Chemotherapy +/- Bevacizumab, and Initiation of Second-line Therapy Using Administrative Claims*. ISPOR 8th Annual European Congress. 2005.

Parrish M, Satariano W, Freisthler B, Feinberg L, **Adams S**. *Older women with breast cancer: Caregiving and the risk of depression - an exploratory analysis*. Social Work in Health Care. 2005, 40:41-59.

## **Urology**

Hu JC, **Elkin EP**, **Pasta DJ**, **Lubeck DP**, Kattan MW, Carroll PR, Litwin MS. *Predicting quality of life after radical prostatectomy: Results from CaPSURE*. Journal of Urology. 2005. 171:703-708.

Hu JC, **Elkin EP**, **Pasta DJ**, **Lubeck DP**, Kattan MW, Carroll PR, Litwin MS. *Predicting quality of life after radical prostatectomy: Results from CaPSURE*. Journal of Urology. 2005. 171 703-708.

Cooperberg MR, **Pasta DJ**, **Elkin EP**, Litwin MS, Latini DM, DuChane J, Carroll PR. *The University of California, San Francisco Cancer of the Prostate Risk Assessment score: A straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy*. Journal of Urology. 2005. 173:1938-1942.

Chan JM, **Elkin EP**, **Silva SJ**, Broering JM, Latini DM, Carroll PR. *Total and specific complementary and alternative medicine use in a large cohort of men with prostate cancer*. 2005. Urology 66 1223-1228.

Meng MV, **Elkin EP**, Latini DM, DuChane J, Carroll PR. *Treatment of patients with high risk localized prostate cancer: Results from Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE)*. Journal of Urology. 2005. 173 1557-1561.

---

ICON Clinical Research  
Lifecycle Sciences Group  
(415) 741-2101

[Deborah.Lubeck@iconplc.com](mailto:Deborah.Lubeck@iconplc.com)



---

Johnson LL, **Miller KL**, **Miller DP**, **Colwell HH**, Bhattacharyya SK, Deeter RG. *Variability in QoL Questionnaires and the Handling of Missing Data in Patients with Non-Small Cell Lung Cancer Treated with Chemotherapy*. International Society for Pharmacoeconomics & Outcomes Research 8th Annual European Congress. 2005.

### **Orthopedics**

Bruce B, Fries JF, **Lubeck DP**. *Aerobic exercise and its impact on musculoskeletal pain in older adults: a 14-year prospective, longitudinal study*. Arth Research Therapy. 2005. 7:1263-1270.

**Lubeck DP**, Hubert HB. *Self-report is a viable method for obtaining health care utilization data in community-dwelling seniors*. J Clin Epi. 2005. 58:286-290.

### **Other**

Mueller-Ohering EM, Schulte T, **Raassi C**, Pfefferbaum A, Sullivan EV. *MRI evidence for callosal involvement in competitive but not parallel local-global processing in alcoholism*. The 28th Annual Meeting of the Research Society on Alcoholism. 2005.

Sassoon SA, Jack A, **Raassi C**, O'Reilly A, Rosenbloom MJ, Pfefferbaum A. *Progression of visuospatial construction and visual memory deficits in the comorbidity of alcoholism and HIV*. 28th Annual Meeting of the Research Society on Alcoholism. 2005.

Rosenbloom MJ, O'Reilly A, Sassoon SA, **Raassi C**, Schulte M, Pfefferbaum A. *Story Recall improves with abstinence in chronic alcoholic men and women*. 28th Annual Meeting of the Research Society on Alcoholism. 2005.

### **Respiratory**

**Neil NN**, Lamm D, **Ogden K**, **Noe LL**, Peterson L, Mallick R. *A simulation model of the cost of treatment failure in patients hospitalized with community-acquired pneumonia (CAP) in the US*. 15th European Congress of Clinical Microbiology & Infectious Diseases. 2005.

**Neil NN**, Lamm D, **Ogden K**, **Noe LL**, Peterson L, Mallick R. *A simulation model of the cost of treatment failure in patients hospitalized with community-acquired pneumonia (CAP) in the US*. Clinical Microbiology and Infection 11 Abstract O59. 2005.

Mascia K, Haselkorn T, Deniz YM, **Miller DP**, Bleecker E, Borish L. *Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma*. J Allergy Clin Immunol. 2005. 116:970-5.

Haselkorn T, Chipps BE, **Miller DP**, Lee JH *Gender differences in patients with IgE-mediated asthma*. American Academy of Asthma, Allergy and Immunology. 2005.

Lee JH, Haselkorn T, **Miller DP**, Weiss ST. *Omalizumab significantly improves quality of life and asthma control in patients with severe or difficult-to-treat asthma*. American College of Asthma, Allergy and Immunology. 2005.



A Symbol of Excellence

---

Miller MK, Johnson C, **Miller DP**, Deniz Y, Bleecker E, Wenzel SE. *Severity assessment in asthma: An evolving concept*. J Allergy Clin Immunol 116 990-5. 2005.

Sullivan SD, **Rasouliyan L**, Russo PA, Kamath TV, Chipps B. *The Burden of Uncontrolled Disease in Moderate and Severe Asthma*. American College of Allergy, Asthma, and Immunology. 2005.

## **Urology**

Michell JA Cooperberg MR **Elkin EP Lubeck DP**. *Ability of two pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: Data from CaPSURE*. 2005. J Urol. 173:1126-31.

Sadetsky N, **Lubeck DP, Pasta DJ**, Latini DM, DuChang J, Carroll PR, *Demographics, insurance coverage, and utilization of medical services in newly diagnosed prostate cancer: Data from CaPSURE*. Manag Care Interface. 2005. 18:25-30.

Latini DM, Penson DF, Wallace KL, **Lubeck DP**, Lue TF. *Longitudinal differences in psychological outcomes for men with erectile dysfunction: results from ExCEED*. J Urology. 2005.

D'Amico AV, Moul J, Carroll PR, **Lubeck DP**, Chen MH. *Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer*. J Urol. 2005.173: 1572-1576.

**Cisternas M, Noe LL**, Patel B, Remigio-Baker R, Williamson T, Black L. *Comparison of Persistence Among Therapies for Overactive Bladder: A Retrospective Pharmacy Claims Analysis*. International Continence Society Annual Meeting. 2005.

Sadetsky N, **Lubeck DP**, Latini DM, **Pasta DJ**, Kawakami J, DuChane J, Carroll PR. 2005 *Demographics, insurance coverage, and utilization of medical services in newly diagnosed prostate cancer: data from CaPSURE*. Manag Care Interface 18(2) 25-30.

Bassett W WCooperberg M RSadetsky N **Silva SJ**, DuChane J, **Pasta DJ**, Chan J, MAnast J, WCarroll P R, Kane C J. *Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE*. Urology. 2005. 66:1060-5.

**Neil NN, Block S, Ogden K, Noe L**, Black L, Williamson T. *Modeling the costs and outcomes of solifenacin vs behavioral therapy or no therapy for treatment of overactive bladder in primary care*. American College of Clinical Pharmacy Annual Meeting. 2005.

Kane CJ, Bassett WW, Sadetsky N, **Silva SJ**, Wallace K, **Pasta DJ**, Cooperberg MR, Chan JM, Carroll PR. *Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE*. J Urol. 2005. 173(3) 732-6.

Anast JW, Sadetsky N, **Pasta DJ**, Bassett WW, Latini D, DuChane J, Chan JM, Cooperberg MR, Carroll PR, Kane CJ. *The impact of obesity on health related quality of life before and after radical prostatectomy (data from CaPSURE)*. J Urol. 2005. 173(4):1132-8.

**Pless R**. *An Introduction to Regular Expressions with Examples from Clinical Data*. Pharmaceutical SAS Users Group. 2005.



A Symbol of Excellence

---

**Rasouliyan L, Pasta DJ**, *Characterizing patterns of Longitudinal Data Completeness through Successive Refinement*. Western Users of SAS Software. 2005.

Hartsfield CL, Shetterly S, Palen TE, **McCoy M**, Marton JP. *COPD: Treatment and utilization patterns in managed care*. American Thoracic Society Meeting: San Diego, CA. 2005.

**Pless R**. *Meta-data That You (Probably) Didn't Know You Had: An Introduction to SAS Dictionaries and Automatic Macro Variables*. Western Users of SAS Software Conference. 2005.

**Pasta DJ**. *Parameterizing models to test the hypotheses you want: coding indicator variables and modified continuous variables*. Thirtieth Annual SAS Users Group International (SUGI) Conference Paper 212-30. 2005.



---

## ICON LIFECYCLE SCIENCES PUBLICATIONS – 2004

---

### **Cardiovascular**

Sanborn T A, Jacobs A K, **Frederick PD**, Every N R, French W J. *Comparability of quality-of-care indicators for emergency coronary angioplasty in patients with acute myocardial infarction regardless of on-site cardiac surgery (report from the National Registry of Myocardial Infarction)*. Am J Cardiol. 2004. 93 1335-9, A5.

Spencer F, Fonarow G, **Frederick PD**, Wright R S, Every N, Goldberg R J, Gore J M, Dong W, Becker R C, French W. 2004 *Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction: national registry of myocardial infarction*. Arch Intern Med 164 2162-8

Bradley E H, Herrin J, Mattera J A, Holmboe E S, Wang Y, **Frederick PD**, Roumanis S A, Radford M J, Krumholz H M. *Hospital-level performance improvement: beta-blocker use after acute myocardial infarction*. Med Care. 2004. 42 591-9.

Wiviott S D, Morrow D A, **Frederick PD**, Giugliano R P, Gibson C M, McCabe C, Cannon C P, Antman E M, Braunwald E. *Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: a simple index that predicts mortality in ST-segment elevation myocardial infarction*. J Am Coll Cardiol. 2004. 44:783-9.

**Parsons LS**. *Performing a 1:n case-control match on propensity score*. Twenty-Ninth Annual SAS® Users Group International (SUGI) Conference invited papers. 2004. 165-29

Manhapra A, Canto J G, Vaccarino V, **Parsons LS**, Kiefe C, Barron H V, Rogers W J, Weaver W D, Borzak S. *Relation of age and race with hospital death after acute myocardial infarction*. Am Heart J. 2004. 148:92-8.

Grzybowski M, Welch R D, **Parsons LS**, Ndumele C E, Chen E, Zalenski R, Barron H V. *The association between white blood cell count and acute myocardial infarction in-hospital mortality: findings from the National Registry of Myocardial Infarction*. Acad Emerg Med. 2004. 11 1049-60

### **Gastroenterology/Digestive Diseases**

Lichtenstein GR, Cohen RD, Feagan BG, Sandborn WJ, Salzberg BA, **Pritchard ML**, **Miller DP**, **Chen DM**, Diamond RH. *Assessment of infliximab and other factors as potential risks for the development of intestinal stricture, stenosis or obstruction in Crohn's Disease - Data from the 6000-patient TREAT Registry*. American College of Gastroenterology (ACG) Annual Conference. 2004.

Lichtenstein G, Cohen R, Feagan B, Sandborn W, Salzberg B, **Chen DM**, Diamond R. *Safety of Infliximab in Crohn's Disease: Data from the 5000-Patient TREAT Registry*. Digestive Disease Week (DDW). 2004.

Lichtenstein GR, Cohen RD, Feagan BG, Sanborn WJ, Salzberg BA, **Chen DM**, Diamond RH. *Safety of infliximab in Crohn's Disease: Data from the TREAT Registry*. 12th United European



---

Gastroenterology Week. 2004.

**Trotter JP, Larson LR, Gordon MJ, Malamis P.** *The role of outcomes researchers in designing patient registries: Creating programs to meet broad organizational objectives.* Ninth Annual International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Meeting. 2004.

### ***Infectious Disease/Immunology***

Mueller-Ohering EM, Schulte T, **Raassi C**, Pfefferbaum A, Sullivan EV. *Differential hemispheric visuospatial functioning in alcoholism, HIV and their comorbidity.* 27th Annual Scientific Meeting of the Research Society on Alcoholism. 2004.

**Graves Jones A**, Dollard S, Pellett P, Downing R, Kataaha P, Mermin J, Lackritz E, Chidzonga M, Chipato T, Mwale M, Shiboski C, Padian N, Osmond D, Hladik W, Martin J. *Regional Differences in KSHV Seroprevalence in Sub-Saharan Africa: Insights on the Origin of the "KS Belt."* The Seventh International Workshop on Kaposi's Sarcoma Associated Herpesvirus and Related Agents, Santa Cruz, CA. 2004.

### ***Neurology/CNS (Mental Health)***

White R, Gammaitoni A, **Cisternas M**, **Miller DP.** *Application of propensity scores to claims data: Correcting biases in drug-prescribing patterns of long-acting opioids \** 2004.

**Cisternas M**, White R, Gammaitoni A, **Miller DP.** *Management of chronic pain with long-acting opioids may contribute to the stabilization of total healthcare costs: Results of a retrospective claims database pharmaco-economic study.* 39th American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibits. 2004.

### ***Oncology***

Lee J, **Turini M**, Botteman MF, Stephens JM, Pashos CL. *Economic burden of head and neck cancer: a literature review.* Eur J Health Econ. 2004 5(1):70-80.

**Miller DP, Colwell HH, Pritchard ML**, Sneeringer RK, Calhoun JC, Calhoun EA. *Xerostomia symptoms: A newly developed patient-reported outcomes questionnaire.* Ninth Annual International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Meeting. 2004.

### ***Ophthalmology***

Colman S S, Jones R, Serdahl C L, Smith F M, **Silva SJ**, Schonfeld W H. *The impact of managed eye care on use of vision services, vision costs, and patient satisfaction.* Value Health. 2004. 7:195-203.

### ***Other***

Parrish M, **Adams S.** *Caregiver comorbidity and the ability to manage stress.* Journal of Gerontological Social Work. 2004 42:41-58.



---

Mueller-Ohering EM, Schulte T, **Raassi C**, Pfefferbaum A, Sullivan EV. *Visuospatial processing in alcoholism and aging: Inhibitory deficits in a global/local Letter task*. International Neuropsychological Society, 32nd Meeting. 2004.

### **Psychiatry**

Miller WB, Severy LJ, **Pasta DJ**. *A framework for modelling fertility motivation in couples*. Popul Stud (Camb). 2004; 58(2):193-205.

### **Respiratory/Pulmonary**

Haselkorn T, Dolan C, Wong D, **Miller D**, Deniz Y, Borish L. *High prevalence of skin test positivity in a cohort of subjects with severe or difficult-to-treat asthma*. The Annual Meeting of the American College of Allergy, Asthma & Immunology. 2004.

Wenzel S, Bleecker E, Miller MK, **Pritchard M**, **Miller D**. *Lack of Agreement between Gina Guidelines and physician assessment of asthma severity*. 14th European Respiratory Society Annual Congress. 2004.

Wenzel S, Bleecker E, Miller MK, **Pritchard M**, Miller M, Deniz Y. *Lack of agreement between GINA guidelines and physician assessment of asthma severity*. Eur Respir J 24 591s. 2004.

### **Rheumatology/Arthritis**

Chiou C, Sherbourne CD, Ofman J, Lee M, **Lubeck DP**, Paulus HE, Weisman M. *Development and validation of Cedars-Sinai Health-Related Quality of Life in Rheumatoid Arthritis (CSHQ-RA) short form instrument*. Arthritis and Rheumatism. 2004. 51:358-364.

**Lubeck DP**. *Patient reported outcomes and their role in the assessment of rheumatoid arthritis*. Pharmacoeconomics. 2004. 22:27-38.

Vij R, **McCoy M**, Singh G, Triadafilopoulos G. *Celecoxib relieves periprocedural arthritis pain in patients undergoing colonoscopy*. *Gastrointestinal Endoscopy*. 2004;59(5):134 [Poster - May .] Digestive Disease Week in New Orleans, LA.

Yelin E, **Cisternas M**, **Pasta DJ**, Trupin L, Murphy L, Helmick CG. *Medical care expenditures and earnings losses of persons with arthritis and other rheumatic conditions in the United States in 1997: total and incremental estimates* *Arthritis Rheum*. 2004. 50:2317-26.

### **Urology**

Cooperberg MR, Broering JB, Litwin MS, **Lubeck DP**, Mehta SS, Carroll PR. *Contemporary management of prostate cancer in the United States: Lessons learned from CaPSURE, a national disease registry*. J Urology. 2004. 171:1393-1401.

D'Amico AV, Moul JW, Carroll PR, Cote K, Sun L, **Lubeck DP**, **Chen MH**. *Intermediate end point for*



A Symbol of Excellence

---

prostate cancer specific mortality following salvage hormonal therapy for prostate specific antigen failure. *J Natl Cancer Inst.* 2004. 96:509-515.

Spleight J, **Silva SJ, Lubeck DP**, Litwin M, Carroll P. *Longitudinal assessment of changes in sexual function and bother in patients treated with external beam radiotherapy or brachytherapy, with and without neoadjuvant androgen ablation.* *Int J Radiation Oncology Biology and Physics* 2004. 60 1066-1075.

D'Amico AV, Moul J, Carroll PR, Sun L, **Lubeck DP**, Chen MH. *Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy.* *J Urology.* 2004. 172:S42-S47.

Cooperberg MR **Lubeck DP**, Meng MV, Mehta SS, Carroll PR. *The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management.* *J Clin Onc.* 2004. 22 2141-2149.

Arredondo SA, Downs TM, **Lubeck DP, Pasta DJ, Silva SJ**, Wallace KL, Carroll PR. *Watchful waiting and health-related quality of life in patients with localized prostate cancer: Data from CaPSURE.* *J Urology.* 2004. 172:1830-1834

Litwin MS, Sadetsky N, **Pasta DJ, Lubeck DP.** *Bowel function and bother after treatment for early stage prostate cancer: a longitudinal quality of life analysis from CaPSURE.* *J Urol.* 2004. 172(2):515-519.

Chan JM, **Silva SJ**, Broering JM, Latini D, Carroll PR. *Complementary and alternative medicine use among men with prostate cancer: Data from CaPSURE®.* 99th Annual Meeting of the American Urological Association. 2004.

Kane CJ, Bassett WW, Sadetsky N, **Silva SJ**, Wallace K, **Pasta DJ**, Copperberg MR Chan JMC Carroll PR 2004 *Is obesity associated with more aggressive prostate cancer? Data from CaPSURE®.* 99th Annual Meeting of the American Urological Association.

Speight JL, **Elkin EP, Pasta DJ, Silva SJ, Lubeck DP**, Carroll PR, Litwin MS. *Longitudinal assessment of changes in sexual function and bother in patients treated with external beam radiotherapy or brachytherapy, with and without neoadjuvant androgen ablation: data from CaPSURE.* *Int J Radiat Oncol Biol Phys.* 2004. 60(4):1066-75.

Elliot SP, Gulati M, **Pasta DJ**, Spitalny GM, Kane CJ, Yee R, Lue TF. *Obstructive lower urinary tract symptoms correlate with erectile dysfunction.* 2004. *Urology* 63(6):1148-52.

Mehta S S, **Lubeck DP**, Sadetsky N, **Pasta DJ**, Carroll P R. *Patterns of secondary cancer treatment for biochemical failure following radical prostatectomy: data from CaPSURE.* *J Urol.* 2004. 171 215-9.

Hu J C, **Elkin EP, Pasta DJ, Lubeck DP**, Kattan M, WCarroll P, Litwin MS. *Predicting quality of life after radical prostatectomy: results from CaPSURE.* *J Urol.* 2004. 171 703-7: discussion 707-8.

Purohit RS, **Silva SJ, Lubeck DP**, Wallace K, Carroll PR. *Predictors of adverse health-related quality of life outcomes in men undergoing androgen deprivation therapy.* 99th Annual Meeting of the



---

American Urological Association. 2004.

**Noe LL**, Sneeringer R Patel B Williamson T 2004 *The implications of poor medication persistence with treatment for overactive bladder*. Manag Care Interface 17 54-60

Greene K L, Meng M V, **Elkin EP**, Cooperberg M R, **Pasta DJ**, Kattan M, WWallace K, Carroll P R. *Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from cancer of the prostate strategic urological research endeavor (capsure)*. J Urol. 2004. 171:2255-9.

Arredondo SA, Downs TM, **Lubeck DP**, **Pasta DJ**, **Silva SJ**, Wallace KL, Carroll PR. *Watchful waiting and health related quality of life for patients with localized prostate cancer: data from CaPSURE*. J Urol. 2004. 172(5 Pt 1) 1830-4.

### **Women's Health**

**Colwell HH**, LoCoco JM, Karvois DL, **Mathias SD**, **Cimms TA**, Friedman AJ. *The Ortho Birth Control Assessment Tool (ORTHO BC-SAT): Reliability and validity of a newly developed satisfaction questionnaire*. 60th Annual Meeting of the American Society for Reproductive Medicine. 2004.

**Mathias SD**, Karvois DL, **Colwell HH**, **Cimms TA**, **Pritchard M L**. *The Ortho Birth Control Satisfaction Assessment Tool (ORTHO BC-SAT): Further testing of the psychometric properties of a new satisfaction questionnaire*. Association of Reproductive Health Professionals Annual Meeting. 2004.

**Mathias SD**, LoCoco JM, Karvois DL **Colwell HH**, **Cimms TA**, Friedman AJ *The Ortho Birth Control Satisfaction Assessment Tool (ORTHO BC-SAT): Reliability and validity of a new satisfaction questionnaire*. 11th Annual Meeting of the International Society of Quality of Life Research (ISOQOL). 2004.

### **Methodologic**

**Frederick PD**. *An approach to record-linkage using propensity score*. Twenty-Ninth Annual SAS® User Group International (SUGI) Conference paper. 2004. 148-29.

**Miller DP**. *Bootstrap 101: Obtain robust confidence intervals for any statistic*. Twenty-Ninth Annual SAS® Users Group International (SUGI) Conference paper. 2004. 193-29.

**Mathias SD**, **Colwell HH**. *Collecting patient-reported outcomes data outside the clinical trial paradigm*. Ninth Annual International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Meeting. 2004.

**Pasta DJ**, **Suhr D**. *Creating scales from questionnaires: PROC VARCLUS vs factor analysis*. Twenty-Ninth Annual SAS® User Group International (SUGI) Conference invited paper. 2004. 205-29.

**Silva SJ**, **Pasta DJ**, **Miller DP**, *Disease Registries: Tricks and tips in the analysis of observational data*. Seventh Annual International Society for Pharmacoeconomics and Outcomes Research (ISPOR)



---

European congress. 2004.

**Pasta DJ, Pritchard ML.** *Head of the CLASS: Impress your colleagues with a superior understanding of the CLASS statement in PROC LOGISTIC.* Twenty-Ninth Annual SAS® User Group International (SUGI) Conference. 2004. 194-29.

**Pless R.** One Hiring Manager's Perspective on Job Searches SQL Server Standard. 2004.

**Pasta DJ, Miller DP.** *Statistical analysis of patient registries: Methods for the most effective use of observational data.* Ninth Annual International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Meeting. 2004.

**Larson LR.** *The continuing evolution of patient registries: Designing programs to meet broad organizational objectives.* ISPOR Connections. 2004. 10:5-6.

**Noe LL, Cisternas M.** *Use and integration of freely available US public use files to answer pharmaco-economic questions: Deciphering the alphabet soup.* Ninth Annual International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Meeting. 2004.

**Larson LR, Noe LL, Mathias SD,** Becker R, Waller H. *Utilizing patient registries to support outcomes research: Integrating observational data within economic analyses, models, and other applications.* 7th Annual European Congress Meeting. 2004.



---

## ICON LIFECYCLE SCIENCES PUBLICATIONS – 2003

---

### **Cardiovascular**

Peterson E D, Pollack C V, Jr, Roe M T, **Parsons LS**, Littrell K A, Canto J G, Barron H V. *Early use of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction: observations from the National Registry of Myocardial Infarction 4*. J Am Coll Cardiol. 2003. 42:45-53.

Sutter R, Tiefenbrunn A J, Bach R G, **Frederick PD**, Hodge M R, Waterman B, Traynor P S, Dunagan C. *Hospital Performance With Myocardial Reperfusion Therapy: Are Hospitals Capable of Meeting Established Guidelines?* Crit Pathw Cardiol. 2003. 2:197-206.

Krumholz H M, Gross C P, Peterson E D, Barron H V, Radford M J, **Parsons LS**, Every N R. *Is there evidence of implicit exclusion criteria for elderly subjects in randomized trials? Evidence from the GUSTO-1 study*. Am Heart J. 2003. 146:839-47.

Reynolds MR, **Neil NN**, Ho KK, Berezin R, Cosgrove R S, Lager R A, Sirois C, Johnson R G, Cohen D J. *Long term clinical and economic outcomes of multivessel coronary stenting compared with bypass surgery: a single-center US experience*. Am Heart J. 2003. 145:334-42.

Grzybowski M, Clements EA, **Parsons LS**, Welch R, Tintinalli A, Ross M, Zalenski R J. *Mortality benefit of immediate revascularization of acute ST-segment elevation myocardial infarction in patients with contraindications to thrombolytic therapy: a propensity analysis*. Jama. 2003. 290:1891-8.

Chen E, Canto J, **Parsons LS**, Peterson E, Littrell K, Every N, RGibson C, M Hochman J, SOhman E, MCheeks M, Barron H V. *Relation between hospital intra-aortic balloon counterpulsation volume and mortality in acute myocardial infarction complicated by cardiogenic shock*. 2003. Circulation. 108:951-7.

Bradley E, Holmboe E, Wang Y, Herrin J, **Frederick PD**, Mattera J, Roumanis S, Radford M, JKrumholz H M. *What are hospitals doing to increase beta-blocker use?* Jt Comm J Qual Saf. 2003. 29:409-15.

### **Dermatology/Cosmetic Surgery**

Warshaw E M, Bowman T, Bodman M A, Kim J J, **Silva SJ**, **Mathias SD**. *Satisfaction with onychomycosis treatment. Pulse versus continuous dosing*. J Am Podiatr Med Assoc. 2003. 93:373-9.

### **Diagnostics/Radiology**

**Miller DP**, Burns R, Schneider A, O'Shaughnessy, Wood S, Castellino R. *A multi-reader, multi-case ROC study demonstrating improved performance detecting lung nodules using computer-aided detection (CAD) in multi-slice CT (MSCT) of the chest (RSNA)*. 89th Scientific Assembly and Annual Meeting. 2003.

### **Endocrinology/Metabolic**

Becker R, Burke T, **McCoy M**, **Trotter J**. *A model analysis of costs of blood pressure destabilization*

---



A Symbol of Excellence

---

and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population. *J. Clin Ther.* 2003. 25(2):647-62.

Kelsh M, Buffler P, Daaboul J, Rutherford G, Lau E, **Exuzides KA**, Cahill J, Palmer L, Lorey F. Primary congenital hypothyroidism and newborn thyroid function among residents of a southern California community. *J. Occup. Environ. Med.* 2003. 45(9):823

### **Gastroenterology/Digestive Diseases**

Sheffield RE, **McCoy M**, Chernicoff HO. *Baseline differences in clinical characteristics among patients using Cox-2 specific inhibitors and nonspecific nonsteroidal anti-inflammatory drugs.* Academy of Managed Care Pharmacy Annual Meeting: Minneapolis, MN. 2003.

Rosh J, Markowitz J, Hyams J, Bouvaros A, Del Rosario J, Evans J, Grand R, Griffiths A, Katz A, Kugathasan S, Mack D, Mezoff A, Oliva-Hemker M, Otley A, Pfefferkorn M, Rothbaum R, Tolia V, Treem W, Wyllie R, **Chen DM**. *Demographic and age-related differences in the presentation of Pediatric Inflammatory Bowel Disease.* National Society for Pediatric Gastroenterology Hepatology and Nutrition (NASPGHAN). 2003.

Markowitz J, Rosh J, Hyams J, Bousvaros A, Del Rosario J, Evans J, Grand R, Griffiths A, Katz A, Kugathasan S, Mack D, Mezoff A, Oliva-Hemker M, Otley A, Pfefferkorn M, Rothbaum R, Tolia V, Treem W, Wyllie R, **Chen DM**. *Does age affect response to initial therapy in children with inflammatory bowel disease (IBD)?* National Society for Pediatric Gastroenterology Hepatology and Nutrition (NASPGHAN). 2003.

Otley A, Griffiths A, Hyams J, Markowitz J, Bousvaros A, Del Rosario J, Evans J, Grand R, Katz A, Kugathasan S, Mack D, Mezoff A, Oliva-Hemker M, Pfefferkorn M, Rosh J, Rothbaum R, Tolia V, **Chen DM**. *Impact-II QOL Questionnaire: Performance in new onset pediatric IBD patients (The Pediatric IBD Collaborative Registry).* Digestive Disease Week (DDW). 2003.

Markowitz J, Hyams J, Griffiths A, Bousvaros A, Del Rosario J, Evans J, Katz A, Kugathasan S, Mack D, Mezoff A, Oliva-Hemker M, Otley A, Pfefferkorn M, Rosh J, Rothbaum R, Tolia V, **Chen DM**. *Initial response to treatment (rx) and need for intensified (step-up) therapy in children with newly diagnosed inflammatory bowel disease (IBD): A preliminary investigation by the Pediatric IBD Collaborative Research Group.* Digestive Disease Week (DDW). 2003.

### **Infectious Disease/Immunology**

Becker R, **Reinhart SP**. *Comparison of two methodologies using gross domestic product to measure affordability of HIV treatment.* Twenty Fifth Annual Meeting of the Society for Medical Decision Making. 2003.

Tholandi M, **Ellman A**, Samuel M, Bolan G, Ruiz J. *Estimation of Syphilis and Gonorrhea Co-morbidity Among AIDS cases in California.* 2003 National HIV Prevention Conference Atlanta, GA. 2003.



A Symbol of Excellence

---

## **Nephrology**

Collins AJ, Kasiske B, Herzog C, Chen SC, Everson S, Constantini E, Grimm R, McBean M, Xue J, Chavers B, Matas A, Manning W, Louis T, Pan W, Liu J, Li S, Roberts T, Dalleska F, Snyder J, Ebben J, Frazier E, **Frederick P**, et al. *Excerpts from the United States Renal Data System 2003 Annual Data Report: atlas of end-stage renal disease in the United States*. Am J Kidney Dis. .2003. 42(6 Suppl 5) A5-7, S1-230.

## **Neurology/CNS (Mental Health)**

Parrish M, Giunta N, **Adams S**. *Parkinson's disease caregiving: Implications for care management*. Care Management Journals. 2003. 4:53-60.

## **Oncology**

Parrish M M, **Adams S**. *An exploratory qualitative analysis of the emotional impact of breast cancer and caregiving among older women*. Care Management Journals. 2003. 4:191-7.

Meng MV, **Elkin EP**, Harlan SR, Mehta SS, **Lubeck DP**, Carroll PR. *Predictors of treatment after initial surveillance in men with prostate cancer: Results from CaPSURE*. Journal of Urology. 2003. 170:2279-2283.

**Turini M**, Radice D, Gramegna P, Redaelli A. *Quality of Life and Economic considerations in the Management of Prostate cancer*. PharmacoEconomics. 2003. 21(8):527-541

Harlan SR, Cooperberg MR, **Elkin EP**, **Lubeck DP**, Meng MV, Mehta SS, Carroll PR. *Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: Results from CaPSURE*. Journal of Urology. 2003. 170:1804-1807.

Kulkarni AD, Taga M, Yamauchi K, Furian L, **Odle J**, Sundaresan A, Pellis NR, Andrassy RJ. *Tumor ground based microgravity analogs and role of nutrition in microgravity*. NASA Cell Science Conference N/A. 2003.

## **Orthopedics**

**Lubeck DP**. *The costs of musculoskeletal disease: Health needs assessment and health economics*. Best Practice. Research Clinical Rheum. 2003. 17:529-539

## **Other**

**Neil NN**. *Improving rates of screening and prevention by leveraging existing information systems*. Jt Comm J Qual Saf. 2003. 29:610-618.

**Neil NN**, Nerenz D. *Learning to leverage existing information systems: Part 1 Principles*. Jt Comm J Qual Saf. 2003. 29:523-30.



---

## **Respiratory/Pulmonary**

**Colwell HH**, Fisher KA, Quittner AL, **Miller K**, **Mathias SD**, Gliklich RE. *An on-line version of the cystic fibrosis questionnaire: Practical uses of "real time" quality-of-life data.* DIA Evaluation Symposium Meeting. 2003.

## **Rheumatology/Arthritis**

Weisman MH, Paulus HD, Russak SM, **Lubeck DP**, Chiou CF, Sengupta N, Ofman JJ, Borenstein J, Moadel AB, Sherbourne CD. *Development of a new instrument for rheumatoid arthritis: The Cedars-Sinai Health-Related Quality of Life Instrument (CSHQ-RA).* Arthritis & Rheumatism. 2003. 49:78-84.

Yelin E, Trupin L, Katz P, **Lubeck DP**, Rush S, Wanke L. *Association between etanercept use and employment outcomes among persons with rheumatoid arthritis.* Arthritis Rheum. 2003. 48:3046-54.

Macario A, **McCoy M**. *The pharmacy cost of delivering postoperative analgesia to patients undergoing joint replacement surgery.* Journal of Pain. 2003. 4(1):22-28.

Russak SM, Sherbourne CD, **Lubeck DP**, Paulus HD, Chiou CF, Sengupta N, Borenstein J, Ofman J, Moadel A, Weisman MH, IN: *2003 Validation of a Rheumatoid Arthritis Health-Related Quality of Life Instrument: the CSHQ-RA.* J of Urology. 2003. 49:798–803.

## **Urology**

D'Amico AV, Moul J, Carroll PR, Sun L, **Lubeck DP**, Chen M-H. *Cancer-specific mortality following surgery or radiation for patients with clinically localized prostate cancer managed during the PSA era.* J Clin Oncol. 2003. 21 2163-2172.

Penson DF Latini DM **Lubeck DP**, Wallace KL and Lue TF 2003. *Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from ExCEED.* Diabetes Care. 26:1093-1099.

Downs TM Grossfeld GD Sadetsky N **Pasta DJ**, Kane CJ Mehta SS Carroll PR **Lubeck DP**. *Health related quality of life patterns in patients treated with interstitial prostate brachytherapy for localized prostate cancer: Data from CaPSURE.* J of Urology. 2003. 170:1822-1827.

Litwin MS, Saigal CS, **Lubeck DP**, Li Y-P, Henning JM, Carroll PR. *Health-related quality of life in men with metastatic prostate cancer: the misleading effect of lead-time bias.* British Journal of Urology International. 2003:91.

Cooperberg MR, Koppie TM, **Lubeck DP**, Ye J, Grossfeld GD, Mehta SS, Carroll PR. *How potent is potent? Evaluation of sexual function and bother in men who report potency after treatment for prostate cancer: Data from CaPSURE.* 2003. Urology. 61.

Penson DF, Latini DM, **Lubeck DP**, Wallace KL, Henning JM, Lue TF. *Is quality of life different for men with erectile dysfunction and prostate cancer compared to men with erectile dysfunction due to other causes? Results from the ExCEED database.* J Urology. 169:1458-1461.



---

Latini DM, Penson DF, **Lubeck DP**, Wallace KL, Henning JM, Lue TF. *Longitudinal differences in disease specific quality of life in men with erectile dysfunction: Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction Study*. J Urology. 2003.169:1437-1442.

Spleight J, **Silva SJ**, **Lubeck DP**. *Long-term longitudinal assessment of changes in sexual function and bother in patients treated with external beam radiotherapy or brachytherapy, with and without neoadjuvant hormone therapy*. J Radiation Oncology. 2003. 57:S222.

Cooperberg MR Grossfeld GD **Lubeck DP**, Carroll PR. *National practice patterns and time trends in androgen ablation for prostate cancer*. J Nat Cancer Inst. 2003. 95:981-9.

Grossfeld GC, Latini DM, **Lubeck DP**, Mehta SS, Carroll PR. *Predicting recurrence after radical prostatectomy for patients with high-risk prostate cancer*. J Urology. 169:157-163.

Harlan SF, Cooperberg MR, **Elkin EP**, **Lubeck DP**, Meng MV, Mehta SS, Carroll PR. *Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: Results from CaPSURE*. J Urology. 2003.170:1804-1807.

Cooperberg MR, **Lubeck DP**, Grossfeld GD, Mehta SS, Carroll PR. *Time trends in clinical risk stratification for prostate cancer: Implications for outcomes: Data from CaPSURE*. J of Urology. 2003. 170:S21-5.

Mehta SS, **Lubeck DP**, **Pasta DJ**, Litwin M. *Fear of cancer recurrence in patients undergoing definitive treatment for prostate cancer: results from CaPSURE*. J Urol. 2003.170:1931-3.

Downs TM, Sadetsky N, **Pasta DJ**, Grossfeld GD, Kane CJ, Mehta SS, Carroll P R, **Lubeck DP**. *Health related quality of life patterns in patients treated with interstitial prostate brachytherapy for localized prostate cancer--data from CaPSURE*. J Urol. 170:1822-7.

Kane CJ, **Lubeck DP**, Knight SJ, Spitalny M, Downs TM, Grossfeld G D, **Pasta DJ**, Mehta SS, Carroll P R. *Impact of patient educational level on treatment for patients with prostate cancer: data from CaPSURE*. Urology. 2003. 62:1035-9.

## **Women's Health**

**Mathias SD**, **Colwell HH**, **Cimms TA**, Karvois DL, LoCoco JM, Friedman AJ. *Measuring treatment satisfaction with hormonal contraceptives: A conceptual framework for a generic measure of satisfaction*. Tenth Annual Meeting of the International Meeting of the International Society for Quality of Life Research (ISOQOL). 2003.

## **Methodological**

**Pasta DJ**, **Cisternas M**. *Estimating standard errors for CLASS variables in generalized linear models using PROC IML*. Twenty-Eighth Annual SAS® Users Group International Conference. 2003: 264-28.

**Silva SJ**. *How to get a graph from a complex linear model*. Eleventh Annual Western Users of SAS®



---

Software Conference .2003.

**Pasta DJ, Cisternas M.** *Presenting logistic regression models to non-statisticians: Adjusted probabilities and adjusted risk ratios.* Eleventh Annual Western Users of SAS® Software Regional User Group Conference. 2003.

Queyrouze B, Pham HT, McKeithen TM, Ross R **McCoy M**, Yaldo A. *Total health benefits and productivity cost impact of musculoskeletal conditions in an employer group.* Academy of Managed Care Pharmacy Educational Conference: Montreal, Quebec, Canada. 2003.

**Parsons LS.** *Using SAS® software and visual basic for applications to produce microsoft graph charts.* Twenty-Eighth Annual SAS® Users Group International Conference paper. 2003:221-8.

**Frederick PD.** *Linkage of patient registries and clinical data sets without patient identifiers.* Twenty-Eighth Annual SAS® Users Group International Conference. 2003:205-28.



A Symbol of Excellence

---

## ICON LIFECYCLE SCIENCES PUBLICATIONS – 2002

---

### **Cardiovascular**

Johnson KE, Patel H, **Reinhart SP**, Lee DW, Warchall SYee M. *Characteristics of patients initiating ARB. Therapy J Managed Care Pharm.* 2002. 8:114.

Innes G, Christenson J, Weaver WD, Liu T Hoekstra J Every N Jackson RE, **Frederick P**, Gibler WB. *Diagnostic parameters of CK-MB and myoglobin related to chest pain duration. CEJM.* 2002. 4:322-30.

Weiss JP, **Parsons LS**, Every NR, Weaver WD, Hlatky MA. *Does Enrollment in a Randomized Clinical Trial Lead to a Higher Cost of Routine Care? American Heart Journal.* 2002. 143:140-144.

Wu A H **Parsons LS**, Every N R, Bates E R. *Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRFMI-2).* J Am Coll Cardiol. 2002. 40: 1389-94.

Gurwitz J H, Goldberg R J ,Malmgren J A, Barron H V, Tiefenbrunn A J, **Frederick PD**, Gore J M. *Hospital transfer of patients with acute myocardial infarction: the effects of age, race, and insurance type. Am J Med.* 2002. 112: 528-34.

Mathew V, Gersh B, Barron H, Every N, Tiefenbrunn A, **Frederick PD**, Malmgren J. *In-hospital outcome of acute myocardial infarction in patients with prior coronary artery bypass surgery. Am Heart J.* 2002. 144:463-9.

Shavelle D M **Parsons LS**, Sada M JFrench W JEvery N R. *Is there a benefit to early angiography in patients with ST-segment depression myocardial infarction? An observational study. Am Heart J.* 2002. 143:488-96.

Angeja BG, Gibson C, MChin R, **Frederick PD**, Every N R, Ross A, Stone G W, Barron H V. *Predictors of door-to-balloon delay in primary angioplasty. Am J Cardiol.* 2002. 89:1156-61.

Elad Y, French W J, Shavelle D M, **Parsons LS**, Sada M J, Every N R. *Primary angioplasty and selection bias inpatients presenting late (>12 h) after onset of chest pain and ST elevation myocardial infarction. J Am Coll Cardiol.* 2002. 39:826-33.

**Neil NN**, Ramsey S D, Cohen D J, Every N R, Spertus J A, Weaver W D. *Resource utilization, cost, and health status impacts of coronary stent versus "optimal" percutaneous coronary angioplasty: results from the OPUS-I trial. J Interv Cardiol.* 2002. 15:249-55.

Every NR, Hallstrom A, McDonald K, **Parsons LS**, Thom D, Weaver D, Hlatky MA. *Sudden Versus Non-Sudden Cardian Death in Patients with Coronary Artery Disease. American Heart Journal.* 2002. 144:390-6.

Goldstein LB, Lyden P, **Mathias SD**, Colman SS **Pasta DJ**, Albers G, Atkinson R, Kelley GNK, Rylander A. *Telephone assessment of functioning and well-being following stroke: is it feasible? J*



---

Stroke Cerebrovasc Dis. 2002. 11:80-7.

Canto J G, Rogers W J, Chandra N C, French W J, Barron H V, **Frederick PD**, Maynard C, Every N R. *The association of sex and payer status on management and subsequent survival in acute myocardial infarction.* Arch Intern Med. 2002. 162:587-93.

Canto J G, Zalenski R J, Ornato J P, Rogers W J, Kiefe C I, Magid D, Shlipak M G, **Frederick PD**, Lambrew C G, Littrell K A, Barron H V. *Use of emergency medical services in acute myocardial infarction and subsequent quality of care: observations from the National Registry of Myocardial Infarction 2.* Circulation. 2002.106:3018-23.

Barnum KR, Szczotka AD, **Reinhart SP**. *2002 Utilization of angiotensin-II receptor antagonists in a managed care pharmacy setting.* J Managed Care Pharm. 2002. 8:109.

### **Diagnostic/Radiology**

**Miller DP**. *Emphasis on CIs when P values are not appropriate.* Radiology. 2002. 224:932-3.

### **Endocrinology/Metabolic**

Schoen EJ, Baker JC, **Colby CJ**, To TT. *Cost-benefit analysis of universal tandem mass spectrometry for newborn screening.* Pediatrics. 2002. 110:781-6.

### **Gastroenterology/Digestive Diseases**

Sullivan SD, Morley J E, Johnson L E, Barber A, Olson J S, Stevens M R, Yamashita B D, **Reinhard SP**, **Trotter JP**, Olave X E. *The GAIN (Geriatric Anorexia Nutrition) registry: the impact of appetite and weight on mortality in a long-term care population.* J Nutr Health Aging. 2002. 6:275-81.

### **Hematology**

Newman DK, **Hoffman S**, Kotamraju S, Zhao T, Wakim B, Kalyanaraman B, Newman PJ. *Nitration of PECAM-1 ITIM tyrosines abrogates phosphorylation and SHP-2 binding.* Biochemical and Biophysical Research Communications. 2002. 296:1171-1179.

### **Infectious Disease/Immunology**

Page-Shafer K, **Graves A**, Kent C, Balls JE, Zapitz VM, Klausner JD. *Increased sensitivity of DNA amplification testing for the detection of pharyngeal gonorrhea in men who have sex with men.* Clin Infect Dis. 2002. 34:173-6.

Shafer KP, Hahn JA, Lum PJ, Ochoa K, **Graves A**, Moss A. *Prevalence and correlates of HIV infection among young injection drug users in San Francisco.* J Acquir Immune Defic Syndr. 2002. 31:422-31.

Osmond DH, Buchbinder, SCheng A, **Graves A**, Vittinghoff E, Cossen CK, Forghani B, Martin JN. *Prevalence of Kaposi sarcoma-associated herpesvirus infection in homosexual men at beginning of and during the HIV epidemic.* Jama. 2002. 287:221-5.



---

## ***Nephrology***

Sheldon D, Lee F, **Neil N**, Ryan J, A Jr. *Surgical treatment of hyperparathyroidism improves health-related quality of life.* Arch Surg. 2002. 137:1022-6: discussion 1026-8.

## ***Oncology***

Kulkarni AD, Taga M, Yamauchi K, Furian L, **Odle J**, Sundaresan A, Pellis NR, Andrassy RJ. *Altered tumor cell growth and tumorigenicity in models of microgravity.* The World Space Congress. 2002.

Reynolds P, Von Behren J, **Elkin EP**. *Birth characteristics and leukemia in young children.* American Journal of Epidemiology. 2002. 155:603-613.

Kulkarni AD, Yamauchi K, **Odle J**, Taga M, Sundaresan A, Pellis. *Perturbation in T cell signal transduction pathway in microgravity.* The World Space Congress. 2002.

Redaelli A, Radice D, **Turini M**. *The Management of Gastric Cancer: Overview Gastrointestinal Oncology.* 2002. 4(4):185-197.

Taga M, Yamauchi K, Furian L, **Odle J**, Sundaresan A, Pellis NR, Andrassy RJ, Kulkarni AD. *Tumor response, immuno surveillance and role of nutrition in microgravity.* ESPEN (European Society for Clinical Nutrition and Metabolism) Congress N/A . 2002.

## ***Other***

**Parsons LS**. *Macros for model building, summarizing, and displaying results of stepwise logistic regressions.* Twenty-Seventh Annual SAS® Users Group International Conference. 2002. 219-27.

Bedrick E **Exuzides KA**, Johnson W 2002 *Predictive influence diagnostics in the accelerated failure time model.* Biostatistics. 2002. 3:331-346.

## ***Psychiatry***

Miller W B, Feldman S S, **Pasta DJ**. *The effect of the nurturant bonding system on child security of attachment and dependency.* Soc Biol. 2002. 49:125-59.

Miller WB, **Pasta DJ**. *The motivational substrate of unintended and unwanted pregnancy.* J of Appl Biobehavioral Res. 2002:7.

## ***Rheumatology/Arthritis***

Bull SA, Conell CA, Campen DH, **McCoy M**. *Relationship of clinical factors to the use of Cox-2 selective NSAIDs within an arthritis population in a large HMO* [\*See Editor's note in J Manag Care Pharm 2002:8(5):405.] J Manag Care Pharm. 2002. 8(4):252-8.



---

## **Urology**

**Lubeck DP**, Grossfeld GD, Carroll PR. *A review of measurement of patient preferences for treatment outcomes after prostate cancer.* Urology. 2002. 60:72-77.

Meng MV, Grossfeld GD, Sadetsky N, Mehta SS, **Lubeck DP**, Carroll PR. *Contemporary patterns of androgen deprivation use for newly diagnosed prostate cancer.* Urology. 2002. 60:7-12.

Cooperberg MR, **Lubeck DP**, Grossfeld GD, Mehta SS, Carroll PR. *Contemporary trends in imaging test utilization for prostate cancer staging: Data from the CaPSUREä Database.* J Urology. 2002. 168:491-495.

Penson DF, Grossfeld GD, Li YP, Flanders SC, **Lubeck DP**, Carroll PR. *How well does the Partin nomogram predict pathologic stage after radical prostatectomy in a community-based population? Results of CaPSURE.* J Urology. 2002. 167:1653-1658.

Grossfeld GD, Latini DM, Downs T, **Lubeck DP**, Mehta SS, Carroll PR. *Is ethnicity an independent predictor of prostate cancer recurrence after radical prostatectomy?* J Urology. 2002. 168:10-25.

Litwin ML, **Lubeck DP**, Spitalny M, Henning, Carroll PR. *Mental health in men treated for early stage prostate carcinoma: A post-treatment, longitudinal quality of life analysis from CaPSURE.* Cancer. 2002. 95:54-60.

Carroll PR, Kantoff PW, Balk SP, Brown MA, D'Amico V, George DJ, Grossfeld GD, Johnson CS, Kelly WK, Klotz L, Lee WR, **Lubeck DP**, McLeod DG, Oh WK, Pollack A, Sartor O, Smith MR, Hart C. *Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer.* Urology. 2002. 60:1-6.

Grossfeld GD Li YP **Lubeck DP**, Carroll PR. *Patterns of failure after primary local therapy for prostate cancer and rationale for secondary therapy.* Urology. 2002. 60:57-62.

Grossfeld GD, Latini D, **Lubeck DP**, Broering JM, Li Y, Mehta SS, Carroll PR. *Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: Results from CaPSUREä.* Urology. 2002. 59:560-565.

Grossfeld GC, Li YP, **Lubeck DP**, Broering JM, Mehta SS, Carroll PR. *Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from CaPSUREä.* J Urology. 2002. 168:530-535.

Katz D, Koppie TM, Wu D, Meng MV, Grossfeld GD, Sadesky N, **Lubeck DP**, Carroll PR. *Sociodemographic characteristics and health related quality of life in men attending prostate cancer support groups.* J Urology. 2002.168:2092-2096.

**Noe LL**, Becker R, Williamson T, **Chen D**. *A pharmacoeconomic model comparing two long-acting treatments for overactive bladder.* J Manag Care Pharm. 2002. 8:343-352.

**Noe LL**, Becker RV, **Chen DM**, Williamson T. *A straightforward cost-effectiveness analysis of long-*

---



---

*acting treatments for overactive bladder: Can it be this simple?* Value Health. 2002. 5:582-583.

Becker RV, **Noe LL**, **Chen DM**, Williamson T. *Evaluating the cost of long-acting treatments for overactive bladder.* Value Health. 2002. 5:583.

Latini D M, Penson D F, **Colwell HH**, **Lubeck DP**, Mehta S S, Henning J M, Lue T F. *Psychological impact of erectile dysfunction: validation of a new health related quality of life measure for patients with erectile dysfunction.* J Urol. 2002. 168:2086-91.

### **Women's Health**

Windham GC, **Elkin EP**, Fenster L, Waller K, Anderson M, Mitchell PR, Lasley B, Swan SH *Ovarian hormones in premenopausal women: Variation by demographic, reproductive and menstrual cycle characteristics.* Epidemiology. 2002. 13:675-384.

### **Methodological**

**Pless R.** *Multi-Stage Modeling: When Two Models Are Better than One* National Center for Database Marketing. 2002.

**Gordon M, Vreeland MG.** *Paper vs electronic data collection in an observational research program.* Drug Information Association Data Management Meeting. 2002.

**Trotter JP.** *Patient registries: A new gold standard for "real world" research.* The Ochsner Journal. 2002. 4:211-4.

**Miller DP.** *Emphasis on CIs when P values are not appropriate.* Radiology. 2002. 224:932-3.



A Symbol of Excellence

---

## ICON LIFECYCLE SCIENCES PUBLICATIONS – 2001

---

### Cardiovascular

Spencer F A, Goldberg R J, **Frederick PD**, Malmgren J, Becker R C, Gore J M. *Age and the utilization of cardiac catheterization following uncomplicated first acute myocardial infarction treated with thrombolytic therapy (The Second National Registry of Myocardial Infarction [NRMI-2]).* Am J Cardiol. 2001. 88:107-11.

Morrow D A, Antman E M, **Parsons LS**, de Lemos J A, Cannon C P, Giugliano R P, McCabe C H, Barron H V, Braunwald E. *Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3.* Jama. 2001. 286:1356-9.

Becker R C, Burns M, Every N, Maynard C, **Frederick PD**, Spencer F A, Gore J M, Lambrew C. *Early clinical outcomes and routine management of patients with non-ST-segment elevation myocardial infarction: a nationwide perspective.* Arch Intern Med. 2001.161:601-7.

Manhapra A, Canto JG, **Parsons LS**, Vaccarino V, Barron HV, Every NR, Kiefe CI, Fogers WJ, Weaver WD, Borzak S. *Higher early mortality among younger blacks after myocardial infarction: Analysis of the National Registry of Myocardial Infarction-2 J.* Am Coll Cardiol. 2001. 37:1A-648A.

Shlipak M G, Angeja B G, Go A S, **Frederick PD**, Canto J G, Grady D. *Hormone therapy and in-hospital survival after myocardial infarction in postmenopausal women.* Circulation. 2001.104:2300-4.

Angeja BG, Shlipak M G, Go A S, Johnston S C, **Frederick PD**, Canto J G, Barron H V, Grady D. 2001 *Hormone therapy and the risk of stroke after acute myocardial infarction in postmenopausal women.* J Am Coll Cardiol 38 1297-301

Wu AH, **Parsons LS**, Every NR, Bates E. Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction. J Am Coll. 2001. Cardiol, 37;1A-648A.

Anderson KM, Califf RM, Stone GW, Neumann FJ, Montalescot G, **Miller DP**, Ferguson JJ, Willerson JT, Weisman HF, Topol EJ. *Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention.* J AM Coll Cardiol. 2001. 37:2059-65.

Sanders G D, Hlatky M A, Every N R, McDonald K M, Heidenreich P A, **Parsons LS**, Owens D K. *Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction.* Ann Intern Med.2001. 135:870-83.

Angeja BG, Chin R, **Frederick PD**, Every NR, Stone G, Ross A, Gibson M, Barron H. *Predictors of door-to-balloon delay in primary angioplasty.* J Am Coll Cardiol. 2001. 37:306A.

Welch R D, Zalenski R J, **Frederick PD**, Malmgren J, Compton S, Grzybowski M, Thomas S, Kowalenko T, Every N R. *Prognostic value of a normal or nonspecific initial electrocardiogram in acute myocardial infarction.* Jama. 2001. 286:1977-84.

---

ICON Clinical Research  
Lifecycle Sciences Group  
(415) 741-2101

[Deborah.Lubeck@iconplc.com](mailto:Deborah.Lubeck@iconplc.com)



---

Pilote L, **Miller DP**, Califf RM, Topol EJ. *Recurrent ischemia after thrombolysis for acute myocardial infarction*. AM Heart J. 2001.141:559-65.

Barron H V, Every N R, **Parsons LS**, Angeja B, Goldberg R J, Gore J M, Chou T M. *The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: data from the National Registry of Myocardial Infarction 2*. Am Heart J. 2001.141:933-9.

Fonarow G C, French W J, **Parsons LS**, Sun H, Malmgren J A. *Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction*. 3 Circulation. 2001.103:38-44.

Canto JG, Zalenski R, Ornator JP, Kiefe CI, Magid D, Shlipak MG, **Frederick PD**, Lambrew CG, Barron HV, for the National Registry of Myocardial Infarction (NRM1) Investigators. *Utilization of the emergency medical system among patients with MI in the reperfusion era: Results from the NRM1 2*. J Am Coll Cardiol. 2001. 37:320A.

### **Dermatology/Cosmetic Surgery**

Chadbourne EB, Zhang S, **Gordon MJ**, Ro EY, Ross SD, Schnur PL, Schneider-Redden PR. *Clinical outcomes in reduction mammoplasty: a systematic review and meta-analysis of published studies*. Mayo Clinic Proceedings. 2001. 76:503-10.

### **Gastroenterology/Digestive Diseases**

Jensen D, Cotler S, Harb G, Poulos NS, Shillington A, **Hasan E**, Vance M. *Comparison of outcomes, treatment selection and completion in hepatitis C patients in academic and community based ambulatory treatment centers*. Hepatology. 2001. 34:422A.

Lichtenstein GR, Keenan G, **Chen DM**, Shakur UM, **Trotter JP**. *Crohn's Disease severity and treatment: Impact on IBDQ scores*. Am J Gastroenterol. 2001. 96:S298.

**Mathias SD**, **Colwell HH**, **Miller DP**, **Pasta DJ**, Henning J, MOfman J, J. *Health-Related quality-of-life and quality-days incrementally gained in symptomatic nonerosive GERD patients treated with lansoprazole or ranitidine*. Dig Dis Sci. 2001. 46:2416-23.

Lichtenstein GR, Bala M, **Gordon MJ**, **Chen DM**. *Impact of Crohn's disease on work status*. Am J Gastroenterol. 2001 96:S298-S299.

Lichtenstein GR, Kennan G, **Vreeland MG**, **Chen DM**. *Infliximab tolerability in Crohn's disease patients*. Am J Gastroenterol. 2001. 96:S298.

Goldstein JL, **Larson LR**, Yamashita B D, Fain J M, Schumock G T. *Low molecular weight heparin versus unfractionated heparin in the colonoscopy peri-procedure period: a cost modeling study*. Am J Gastroenterol. 2001. 96:2360-6.



---

### **Neurology/CNS (Mental Health)**

**Noe LL**, Hankin CS. *Health outcomes of childhood attention deficit/hyperactivity disorder (ADHD): Health care use and work status of caregivers.* ISPOR Sixth Annual International Meeting. 2001. 4:142-3.

**Noe LL.** *Impact of attention-deficit/hyperactivity disorder (ADHD) on healthcare use and work status: A study of caregivers.* J Manag Care Pharmacy. 2001. 7:133.

### **Oncology**

Reynolds P, **Elkin EP**, Scalf R, Von Behren J, Neutra RR. *A case-control pilot study of traffic exposures and early childhood leukemia using a geographic information system.* Bioelectromagnetics. 2001. Suppl 5:S58-S68.

Becker R, **Noe LL**, Gore M, **Chen D.** *Incorporating clinical level-of-evidence criteria into a breast cancer treatment model for Japan.* ISPOR Fourth Annual European Congress. 2001. 4:421.

**Turini M**, Redaelli A. *Primary brain tumors: a review of research and management.* Int.J of Clinical Practice. 2001. 55(7):471-475.

### **Psychiatry**

Miller WB **Pasta DJ.** *Motivational antecedents to contraceptive method change following a pregnancy scare: a couple analysis.* Soc Biol. 2001. 48:256-77.

### **Respiratory/Pulmonary**

Ebi K, **Exuzides KA**, Lau E, Kelsh M, Barnstorm A. *Association of normal weather periods and El Nino events with viral pneumonia hospitalization in females: California, 1993-1998.* American Public Health Assoc. 2001. 91:1200-1208.

### **Rheumatology/Arthritis**

Becker RV, Burke T, Williamson T, **Trotter JP.** *An economic evaluation of the cost of edema and systolic blood pressure destabilization in cox-2-treated patients with osteoarthritis and hypertension.* ISPOR 4th Annual European Congress. 2001. 4:485.

Kavanaugh A, Patel K, Bala M, **Noe LL**, Antoni, A. *Economic impact of infliximab treatment in rheumatoid arthritis - correlation with disease activity score.* Ann Rheum Dis. 2001. 60:279.

### **Urology**

**Lubeck DP**, Kim H, Grossfeld G, Ray P, Penson DF, Flanders SC, Carroll PR. *Health-related quality of life differences between black and white men with prostate cancer: Data from CaPSUREä.* J Urology. 2001. 166:2281-2285.



---

**Lubeck DP**, Grossfeld G, Koppie J, Ye J, Henning JM, Carroll PR. How potent is potent? *Evaluation of sexual function and bother in men who report potency: data from CaPSUREä*. J Urology. 2001.165:190-196.

Moul JW, Connelly RR, **Lubeck DP**, Bauer JJ, Sun L, Flanders SC, Grossfeld GD, Carroll PR. *Predicting risk of PSA-recurrence after radical prostatectomy with the Center for Prostate Disease Research and CaPSUREä databases*. J Urology. 2001. 166:1322-1327.

Litwin MS, **Lubeck DP**, Stoddard ML, **Pasta DJ**, Flanders SC, Henning JM. *Quality of life before death in men with prostate cancer*. J Urology. 2001. 165:871-875.

**Lubeck DP**, Grossfeld GD ,Carroll PR. *The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer*. Urology. 2001. 58:94-100.

Grossfeld GD, Chang JJ, Broering JM, Li YP, **Lubeck DP**, Flanders SC, Carroll PR. *Understaging and undergrading in a contemporary series of patients undergoing radical prostatectomy: results from the CaPSUREä database*. J Urology. 2001.165:851-856.

Penson D, Stoddard ML, **Pasta DJ**, **Lubeck DP**, Flanders SC, Litwin MS. *The impact of socioeconomic status and health insurance coverage on quality of life outcomes in men with prostate cancer*. J Clin Epi. 2001. 54:127-135.

Becker RV, **Noe LL**, **Trotter JP**, Williamson TE. *A cost-effective comparison of extended-release tolterodine (Detrol LA) versus controlled-release oxybutynin (Ditropan XL)*. South Central Section of the American Urological Association Annual Conference. 2001.

Litwin M S, **Lubeck DP**, Stoddard M L, **Pasta DJ**, Flanders S C, Henning J M. *Quality of life before death for men with prostate cancer: results from the CaPSURE database*. J Urol. 2001.165:871-5.

Penson D F, Stoddard M L, **Pasta DJ**, **Lubeck DP**, Flanders S C, Litwin M S. *The association between socioeconomic status, health insurance coverage, and quality of life in men with prostate cancer*. J Clin Epidemiol. 2001. 54:350-8.

### **Women's Health**

Becker R, **Noe LL**, Gore M, Martino S. *A new approach to disease modeling with numerous comparators and multiple decision trees*. ISPOR 6th Annual International Meeting. 2001. 4:189-190.

Becker RV, **Noe LL**, Gore M, Martino S, Eiserman W, Namer M, Howell A, Bianco A, Wantanabe T. *Disease modeling: Developing the infrastructure for a comprehensive, multinational, clinical and economic breast cancer treatment model*. ISPOR 6th Annual International Meeting. 2001. 4:93.

### **Methodological**

**Pless R**. *Mathematical Modeling for Non-Statisticians*. Chicago Association of Direct Marketing Basic



---

Course . 2001.

Hufford MR, **Noe LL**. *Patient-reported outcomes: A comparison of two data-capture methods*. ISPOR Fourth Annual European Congress. 2001. 4:409.

**Parsons LS**. *Reducing bias in a propensity score matched-pair sample using greedy matching techniques*. Twenty-Sixth Annual SAS® Users Group International Conference paper. 2001:214-26.

Becker R, **Noe LL**, Gore M, **Chen D**. *Using level-of-evidence criteria in the evaluation of pharmacoeconomic results*. ISPOR Fourth Annual European Congress. 2001. 4:432.



A Symbol of Excellence

---

## ICON LIFECYCLE SCIENCES PUBLICATIONS – 2000

---

### **Anesthesiology/General Surgery**

**Pasta DJ.** Using propensity scores to adjust for group differences: *Examples comparing alternative surgical methods*. Twenty-Fifth Annual SAS® Users Group International Conference invited paper 261-25. 2000.

### **Cardiovascular**

Canto JG, Shilpak MG, Rogers WJ, Malmgren JA, **Frederick PD**, Lambrew CT, Ornato JP, Kiefe CI for the National Registry of Myocardial Infarction 2 Investigators. 2000. *Chest pain and myocardial infarction: Is it time to redefine the classical clinical presentation? Observations from the NRM12*. J Am Coll Cardiol. 2000. 35:380A.

Canto JG, Ornato JP, Zalenski R, Rogers WJ, **Frederick PD**, Malmgren J, Barron HV, Terndrup TE, Kiefe CI, for the National Registry of Myocardial Infarction 3 Investigators. *Chest pain emergency units and their impact on processes of care and outcome: Observations from the National Registry of Myocardial Infarction 3*. J Am Coll Cardiol. 2000. 35:377A.

Chadbourne EB, Allen IE, Luo D, **Gordon MJ.** *Comparison of BP lib-IIIa Receptor Inhibitors in patients Undergoing Percutaneous Coronary Interventions: A Meta-Analysis*. Abstract accepted to the European Society of Cardiology, 12th Congress. 2000.

Barsness G, Gersh B, Barron H, **Parsons LS**, Every NR. *Early ACE inhibitor treatment is associated with improved hospital outcome in both diabetics and non-diabetics after acute myocardial infarction*. Circulation 102 795( #3839). 2000.

Goodman M, Paustenbach DJ, Sipe K, Malloy CD, Chapman PS, Burke ML, Figueroa R, Zhao K **Exuzides KA.** *Epidemiologic study of pulmonary obstruction in workers occupationally exposed to ethyl- and methyl-cyanoacrylate*. Journal of Toxicology and Environmental Health. 2000. 59:135-164.

Brieger DB, Mak KH, **Miller DP**, Califf RM, Topol EJ. *Hierarchy of risk based on history and location of prior myocardial infarction in the thrombolytic era*. GUSTO-I Investigators. Am Heart J. 2000. 140:29-33.

Vaccarino V, **Parsons LS**, Every N, Barron H, Krumholz H. *Impact of history of diabetes mellitus on hospital mortality in men and women with first acute myocardial infarction The National Registry of Myocardial Infarction 2 Participants*. Am J Cardiol. 2000. 85:1486-9: A7.

Shavelle DM, **Parsons LS**, Sada MJ, French WJ, Every NR, for the National Registry for Myocardial Infarction Investigators. *Is there a benefit of early angiography in ST segment depression myocardial infarction? An observational study*. J Am Coll Cardiol. 2000. 35:403A-404A.

Cannon CP, Gibson CM, Lambrew CT, Tiefenbrunn AJ, Sun H, Malmgren JA, **Frederick PD**, Every NR, Zalenski R, for the National Registry of Myocardial Infarction 2 and 3 Investigators. *Longer thrombolysis door-to-needle times are associated with increased mortality in acute myocardial*

---

ICON Clinical Research  
Lifecycle Sciences Group  
(415) 741-2101

[Deborah.Lubeck@iconplc.com](mailto:Deborah.Lubeck@iconplc.com)



A Symbol of Excellence

---

*infarction: An analysis of 85,589 patients in the National Registry of Myocardial Infarction 2 & 3.* J Am Coll Cardiol. 2000. 35:376A.

Weaver W D, Reisman M A, Griffin J J, Buller C E, Leimgruber P P, Henry T, D'Haem C, Clark V L, Martin J S, Cohen D J, **Neil NN**, Every N R. *Optimum percutaneous transluminal coronary angioplasty compared with routine stent strategy trial (OPUS-1): a randomised trial.* Lancet. 2000. 355:2199-203.

Canto J G, Shlipak M G, Rogers W J, Malmgren J A, **Frederick PD**, Lambrew C T, Ornato J P, Barron H V, Kiefe C I. *Prevalence, clinical characteristics, and mortality among patients with myocardial infarction presenting without chest pain.* Jama. 2000. 283:3223-9.

Magid D J, Calonge B N, Rumsfeld J S, Canto J G, **Frederick PD**, Every N R, Barron H V. *Relation between hospital primary angioplasty volume and mortality for patients with acute MI treated with primary angioplasty vs thrombolytic therapy.* Jama. 2000. 284:3131-8.

Rogers W J, Canto J G, Lambrew C T, Tiefenbrunn A J, Kinkaid B, Shultz D A, **Frederick PD**, Every N. *Temporal trends in the treatment of over 15 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3.* J Am Coll Cardiol. 2000. 36:2056-63.

Shlipak M, Go A, Angija B, **Frederick PD**, Canto J. *The association of post-menopausal estrogen therapy with survival after myocardial infarction.* Circulation. 2000. 102:837(#4023).

Canto JG, Every NR, Magid D, Rogers WJ, Malmgren JA, **Frederick PD**, French WJ, Tiefenbrunn AJ, Misra VK, Kiefe CI, Barron HV, for the National Registry of Myocardial Infarction Investigators. *The relationship of primary angioplasty volume and survival among interventional hospitals in the National Registry of Myocardial Infarction.* 2000. J Am Coll Cardiol. 35 20A,1062-83.

Canto JG, Every N, Magid D, Rogers W, Malmgren JA, **Frederick PD**, French W, Tiefenbrunn A, Misra V, Kiefe C, Barron H. *The volume of primary angioplasty procedures and survival after acute myocardial infarction.* National Registry of Myocardial Infarction 2 Investigators N Engl J Med. 2000. 342:1573-80.

Shlipak M, Go A S, **Frederick PD**, Malmgren J, Barron H V, Canto J G. *Treatment and outcomes of left bundle-branch block patients with myocardial infarction who present without chest pain.* National Registry of Myocardial Infarction 2 Investigators. J Am Coll Cardiol. 2001. 36:706-12.

**Parsons LS.** *Using SAS® software to perform a case-control match on propensity score in an observational study.* Twenty-Fifth Annual SAS® Users Group International Conference paper. 2000. 225-25

### **Dermatology/Cosmetic Surgery**

Cher D, **Exuzides KA.** *A latex sensitization study using the national health and nutrition examination survey.* Annual Meeting of the Society of Toxicology Philadelphia, PA. 2000.

---

ICON Clinical Research  
Lifecycle Sciences Group  
(415) 741-2101

[Deborah.Lubeck@iconplc.com](mailto:Deborah.Lubeck@iconplc.com)



---

## **Gastroenterology/Digestive Diseases**

Feagan BG, **Vreeland MG**, Larson LR, Bala MV. *Annual cost of care for Crohn's disease: a payor perspective.* Am J Gastroenterol. 2000. 95:1955-60.

Ofman JJ, Yamashita B, Siddique RM, **Larson LR**, Willian MK. *Cost effectiveness of rabeprazole versus generic ranitidine for symptom resolution in patients with erosive esophagitis.* Am J Manag Care 2000. 6:905-16.

Sandborn WJ, Lichtenstein GR, Feagan BG, Hanauer SB, Hyams J, Salzberg B, Schaible T, **Vreeland MG**, Larson LR, Mummert LH, **Trotter JP**. *Long-term impact of Crohn's disease pharmacotherapy: TREAT registry baseline results.* Capri 2000: International Meeting on Inflammatory Bowel Diseases. 2000.

**Miller DP**, Pasta DJ, Mathias SD, Colwell HH, Henning JM. *Quality-Days Incrementally Gained (QDIG): A new approach for short-term evaluations based on the extended Q-TWiST (EQT) method illustrated in a clinical study of reflux disease patients.* Drug Information Journal. 2001. 34:469-81.

Cohen R, **Larson LR**, Roth J, Becker R, Mummert L. *The cost of hospitalization in Crohn's disease.* Am J Gastroenterol. 2000. 95:524-30.

Sandborn WJ, Feagan BG, Hanauer SB, Lichtenstein GR, Salzberg B, Hyams J, Schaible T, **Vreeland MG**, Larson LR, **Trotter JP**, Mummert LH, **Chen DM**. *TREAT registry results: Correlations between physician assessments of disease severity and IBDQ in Crohn's disease patients.* American College of Gastroenterology (ACG) Annual Conference. 2000.

## **Infectious Disease/Immunology**

Hartogensis W, **Graves A**, Schultz K, Louie L. *Comparing tree-based survival analysis and proportional hazard models using generic predictors of progression to AIDS.* 33rd Annual Meeting of the Society for Epidemiologic Research, Seattle, WA. 2000.

Page-Shafer K, Hahn J, **Graves A**, Ochoa K, Lum P, Evans J, Moss A. *HIV is Associated with Sexual Risk and HCV with Injection Risk Among Young Injection Drug Users in San Francisco.* XIII International Conference on AIDS. Durban, South Africa. 2000.

Page-Shafer K, Alves K, **Graves A**, Caseiro M, Rawal B, Sucupira C, Guevara G, Diaz R, Hendry M, Rutherford G, Coates T. *Increased incidence of HIV and evidence of transmission of resistant virus among anonymous test site (ATS) attendees in Santos, Brazil, 1995-1999.* XIII International Conference on AIDS, Durban, South Africa. 2000.

Martin J, Lee T, Busch M, Cheng A, **Graves A**, Klencke B, Cossen C, Forghani B, Osmond D. *Salivary Shedding of KSHV Among Homosexual Men.* 3rd International KSHV and Related Rhadinovirus Workshop, Amherst, MA. 2000.



---

### **Nephrology**

Ross S, Dong E, **Gordon MJ**, Connelly J, Kvasz Mlyengar M, Muais S. *Meta-Analysis of Outcome Studies in End-Stage Renal Disease*. *Kidney International*. 2000. 57:S28-38.

### **Oncology**

**Noe LL**, Becker RV, Gore M, Martino S, Siermann W, Namer M, Howell A, Bianco AR, Wantabe T, **Chen DM**. *An approach to designing a multi-national model for the current treatment of breast cancer*. ISPOR 3rd Annual European Conference. 2000. 3:353.

Grossfeld GD, Chang JJ, Broering JM, **Miller DP**, Yu J, Flanders SC, Carroll PR. *Does the completeness of prostate sampling predict outcome for patients undergoing radical prostatectomy?* *Urology*. 2000. 56:430-5.

Kelsh M, Chapman P, Bracken TD, Sahl JD, Rankin R, **Exuzides KA**. *Female breast cancer feasibility study: A comparison of magnetic fields exposures in a garment manufacturing and electric utility work environment*. 2000. EPRI Palo Alto, CA TR-114845.

Grossfeld GD, Chang JJ, Broering JM, **Miller DP**, Yu J, Flanders SC, Henning JM, Stier DM, Carroll PR. 2000 *Impact of positive surgical margins on prostate cancer recurrence and the use of secondary cancer treatment: data from the CapSURE database*. *J Urol*. 2000. 163:1171-7.

Morgan R, Kelsh M, Zhao K, **Exuzides KA**, Heringer S, Negrete W. *Radiofrequency exposure and mortality from cancers of the brain and lymphatic/hematopoietic systems*. *Epidemiology*. 2000.11:118-127.

### **Ophthalmology**

Zilberberg M, Levine C, Guldin M, **Gordon MJ**, Chadbourne E. *Efficacy and Safety of Gamma-Linolenic Acid (GLA): A Systematic Review of the Literature*. Abstract accepted to the American Oil Chemists Society, 91st Annual Meeting and Expo. 2000.

### **Orthopedics**

Satterfield T, Johnson S, MSlovic P, **Neil NN**, Schein JR. *Perceived risks and reported behaviors associated with osteoporosis and its treatment*. *Women Health*. 2000. 31:21-40.

### **Psychiatry**

**Pasta DJ**, Miller WB. *A heritability study of childbearing motivation Genetic Influences on Human Fertility and Sexuality*. Theoretical and Empirical Contributions from the Biological and Behavioral Sciences. 2000:107-20.

Miller WB, **Pasta DJ**. *Early family environment, reproductive strategy and contraceptive behavior: testing a genetic hypothesis Genetic Influences on Human Fertility and Sexuality*. Theoretical and Empirical Contributions from the Biological and Behavioral Sciences. 2000. 183-230.



---

Miller WB, **Pasta DJ**, MacMurray J, Muhleman D, Comings DE. *Genetic influences on childbearing motivation: further testing a theoretical framework Genetic Influences on Human Fertility and Sexuality. Theoretical and Empirical Contributions from the Biological and Behavioral Sciences.* 2000: 35-66

### **Respiratory/Pulmonary**

**Mathias SD**, Warren EH, **Colwell HH**, Sung JC. *A new treatment satisfaction measure for asthmatics: a validation study.* Qual Life Res. 2000. 9:873-882.

**Trotter JP.** *The treatment of seasonal allergic rhinitis: cost implications of pharmacotherapy for managed care.* Manag Care Interface. 2000.13:60-2.

Kavanaugh A, Patel K, Bala M, **Noe LL.** *Cost-effectiveness of infliximab in rheumatoid arthritis.* Arthritis Rheum. 2000. 43:S144.

**Mathias SD, Colwell HH, Miller DP,** Moreland L W, Buatti M, Wanke L. *Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo.* Clin Ther. 2000. 22:128-39.

### **Urology**

**Lubeck DP,** Litwin MS, Henning JM, **Mathias SD,** Bloor L, Carroll PR. *An instrument to measure patient satisfaction with health care in an observational database: Results of a Validation Study from CaPSURE.* American Journal of Managed Care. 2000:6.

**Lubeck DP,** Grossfeld G, Flanders SC, Ray P, Penson D, Carroll PR. *Differences in health-related quality of life between African American and Caucasian men with prostate cancer: data from CaPSURE.* Value in Health. 2000. 3:54.

**Lubeck DP,** Grossfeld G, Ray PS, Flanders S, Penson D, Carroll PR. *Health-related quality of life and sociodemographic profiles of African-American men with prostate cancer.* J Urology. 2000.163:16.

**Lubeck DP,** Litwin MS, Li YP, Flanders SC, Carroll PR. *Quality of life after metastatic prostate cancer.* J Urology. 2000. 163:17.

**Lubeck DP,** Litwin MS, Henning J, **Mathias SD,** Bloor L, Carroll P. *An instrument to measure patient satisfaction with healthcare in an observational database: results of a validation study using data from CaPSURE.* Am J Manag Care. 2000. 6:70-6.

Schoen EJ **Colby CJ,** Ray GT. *Newborn circumcision decreases incidence and costs of urinary tract infections during the first year of life.* Pediatrics. 2000. 105:789-93.

Litwin MS, **Pasta DJ,** Yu J, Stoddard ML, Flanders SC. *Urinary function and bother after radical prostatectomy or radiation for prostate cancer: a longitudinal, multivariate quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor.* J Urol. 2000. 164:1973-7.



A Symbol of Excellence

---

**Lubeck DP**, Litwin MS, Henning JM, **Mathias SD**, Bloor L, Carroll PR. *Validation of an instrument to measure patient satisfaction with health care in an observational database: Data from CaPSURE™*. Am J Manag Care. 2000. 6:70-6.

### **Women's Health**

Georgieff MK, Wobken JK, **Welle J**, Burdo JR, Connor JR. *Identification and Localization of Divalent Metal Transporter (DMT-1) in Term Human Placenta*. Placenta. 2000. 21:799-804.

### **Methodological**

Kvasz M, Allen IE, **Gordon MJ**, Ro EY, Estok R, Olkin I, Ross SD. *Adverse Drug Reactions in Hospitalized Patients: A Critique of a Meta-Analysis* Medscape. General Medicine Online Journal. 2000. 27:3.

**Noe LL**, Peebles P. *Medical resource consumption by patients with chronic and breakthrough pain*. ISPOR 5th Annual International Meeting. 2000. 3:84.

Ray GT, Collin F, Lieu T, Fireman B, **Colby CJ**, Quesenberry CP, Van den Eeden SK, Selby JV. *The cost of health conditions in a health maintenance organization*. Med Care Res Rev. 2000. 57:92-109.

---

ICON Clinical Research  
Lifecycle Sciences Group  
(415) 741-2101

[Deborah.Lubeck@iconplc.com](mailto:Deborah.Lubeck@iconplc.com)



A Symbol of Excellence

---

## ICON LIFECYCLE SCIENCES PUBLICATIONS – 1999

---

### **Cardiovascular**

Every N R, **Frederick PD**, Robinson M, Sugarman J, Bowlby L, Barron H V. *A comparison of the national registry of myocardial infarction 2 with the cooperative cardiovascular project.* J Am Coll Cardiol. 1999. 33:1886-94.

**Noe LL**, **Vreeland MG**, Pezzella S, Trotter **JP**. *A pharmaco-economic assessment of torsemide and furosemide in the treatment of patients with congestive heart failure.* Clin Ther. 1999. 21:854-866.

Weiss JP, **Reinhard SP**, Yamashita BD. *Abciximab utilization, costs, and outcomes in patients undergoing percutaneous revascularization.* American Heart Association 72nd Scientific Session. 1999.

Ramsey S D, **Neil NN**, Sullivan S, DiPerfetto E. *An economic evaluation of the JNC hypertension guidelines using data from a randomized controlled trial.* Joint National Committee. J Am Board Fam Pract. 1999. 12:105-14.

Vaccarino V, **Parsons L**, Every N R, Barron H V, Krumholz H M. *Sex-based differences in early mortality after myocardial infarction National Registry of Myocardial Infarction 2 Participants.* N Engl J Med. 1999. 341:217-25.

Narins CR, **Miller DP**, Califf RM, Topol EJ. *The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of the lib/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications.* J Am Coll Cardiol. 1999. 33:647-53.

### **Dermatology/Cosmetic Surgery**

**Lubeck DP**, Schein JR, Gause D, Potter L, Prebil LA. *Health-related quality of life in patients with onychomycosis: data from a 9-month observational study.* J Clin Outcomes Management. 1999. 6:37-44.

**Lubeck DP**, Gause D, Schein J R, Prebil L E, Potter L P. *A health-related quality of life measure for use in patients with onychomycosis: a validation study.* Qual Life Res. 1999. 8:121-9.

**Lubeck DP**, Rich P, Schein JR, Doyle JJ, Prebil L, Potter L. *Changes in health-related quality of life in patients with onychomycosis.* 57th Annual Meeting of the American Academy of Dermatology. 1999.

**Lubeck DP**, Schein JR, Gause D, Prebil LE, Potter LP. *Health-related quality of life in patients with toenail onychomycosis: data from a 9-month observational study.* J Clin Outcomes Manage. 1999. 6:37-42.

---

ICON Clinical Research  
Lifecycle Sciences Group  
(415) 741-2101

[Deborah.Lubeck@iconplc.com](mailto:Deborah.Lubeck@iconplc.com)



---

## **Gastroenterology/Digestive Diseases**

Schwartz C E, **Mathias SD, Pasta DJ, Colwell HH**, Rapkin B D, Genderson M W, Henning J M. *A comparison of two approaches for assessing patient importance weights to conduct an Extended Q-TWiST analysis*. Qual Life Res. 1999. 8;197-207.

Feagan BG, **Larson LR, Vreeland MG**, Bala MV. *Annual cost of care for Crohn's disease patients*. American Gastroenterological Association (AGA) Annual Scientific Meeting. 1999.

**Mathias SD, Pasta DJ, Colwell HH**, Howden CW. *Assessment of HRQOL in heartburn patients: results from a community-based crossover study*, *Gastroenterology*. Gastroenterology. 1999.116:Abstract A79.

Morley JE, Johnson LE, Sullivan DH, Elliott J, Barber A, Olson JS, Stevens MR, Yamashita BD, **Reinhard SP, Trotter JP**. *Characteristics of institutionalized geriatric patients upon discovery of a nutritional problem: The GAIN (Geriatric Anorexia Nutrition) registry*. American Medical Directors Association (AMDA) Conference. 1999.

Ofman JJ, Yamashita BD, Siddique RS, **Larson LR**, Willian MK. *Cost-effectiveness of proton pump inhibitor maintenance therapies: A one-year decision-analysis model*. American College of Gastroenterology (ACG) Annual Conference. 1999.

Ofman JJ, Yamashita BD, Siddique RS, **Larson LR**, Willian MK. *Cost-effectiveness of rabeprazole versus ranitidine in reflux esophagitis*. Fourth Annual International Meeting (ISPOR). 1999. 2:154.

**Colwell HH, Mathias S D, Pasta DJ**, Henning J M, Hunt R H. *Development of a health-related quality-of-life questionnaire for individuals with gastroesophageal reflux disease: a validation study*. Dig Dis Sci. 1999 44 1376-83

Morley JE, Johnson LE, Sullivan DH, Olson JS, Yamashita BD, **Reinhard SP**. *Nutrition in the nursing home: Nutritional characteristics of institutionalized elderly*: The GAIN (Geriatric Anorexia Nutrition) registry Gerontological Society of America (GSA) 52nd Annual Scientific Meeting. 1999.

Ofman JJ, Yamashita BD, Siddique RS, **Larson LR**, Willian MK. *The cost-effectiveness of rabeprazole versus rantidine in the management of reflux esophagitis*. American Gastroenterological Association (AGA) Annual Scientific Meeting. 1999.

## **Hematology**

Francis CW, Pleil AM, **Reinhard SP**, Cohen B. *A prospective, pharmacoeconomic evaluation of fragmin in total hip replacement surgery*. P & T 24. 1999. 136-143.

Pleil AM, Calais M, **Vreeland MG, Reinhard SP**, Mummert LH, **Trotter JP**. *An economic assessment of dalteparin versus warfarin in total hip replacement*. Second Annual European Conference (ISPOR) 2. 1999:350-351.



---

### ***Infectious Disease/Immunology***

Hartogensis W, **Graves A**, Schultz K, Stephens E, Louie L. *Genetic contribution to the risk of developing manifestations of AIDS*. 25th Annual Meeting of the American Society for Histocompatibility and Immunogenetics, 1999. New Orleans, LA .

**Graves A**, Schultz K, Louie L. *Genetic Contributions to Developing AIDS*. 32nd Annual Meeting of the Society for Epidemiologic Research, 1999. Baltimore, MD.

**Trotter JP**. *Health economic considerations in HIV treatment In advances in the management of human immunodeficiency virus infection: Implications for Managed Care*. Managed Care Interface Suppl. 1999.

### ***Neurology/CNS (Mental Health)***

**Noe LL**, Jackson S, Peeples P. *Impact of attention deficit and hyperactivity disorder (ADHD): A survey of primary caregivers*. Value Health. 1999. 2:195.

### ***Oncology***

Reynolds P, **Elkin EP**, Layefsky ME, Lee GM. *Cancer in California school employees*. American Journal of Industrial Medicine. 1999. 36:271-278.

Gann PH, Klein KG, Chatterton RT, **Ellman AE**, Grayhack JT, Nadler RB, Lee C. *Growth factors in expressed prostatic fluid from men with prostate cancer, BPH, and clinically normal prostates*. Prostate. 1999. 6:248-55.

**Noe LL**, **Vreeland MG**, Gore MG, **Trotter JP**. *Initial, maintenance, and terminal care costs of breast cancer treatment Fourth Annual International Meeting (ISPOR)*. 1999. 2:195.

**Trotter JP**. *The cost-effectiveness of tamoxifen in the prevention of breast cancer Safeguarding the health of women at high risk for breast cancer*. Seminar sponsored by Zeneca Pharmaceuticals. 1999.

### ***Psychiatry***

Miller WB, **Pasta DJ**, MacMurray J, Chiu C, Wu H, Comings D E. *Dopamine receptor genes are associated with age at first sexual intercourse*. J Biosoc Sci. 1999. 31:43-54.

Miller WB, **Pasta DJ**, MacMurray J, Chiu C, Wu H, Comings DE. *Genetic influences on childbearing motivation: A theoretical framework and some empirical evidence Advances in population. Psychosocial perspectives*. 1999. 3:53-102.

### ***Rheumatology/Arthritis***

Katz PP, Yelin EH, **Lubeck DP**, Wanke LA, Buatti M. *Determinants of RA patients' global health status ratings*. Arthritis & Rheumatism. 1999. 42:S73.



---

## **Urology**

**Lubeck DP**, Prebil LA, Peebles P, Brown JS. *A health-related quality of life measure for use in patients with urge urinary incontinence: a validation study*. Quality of Life Research. 1999. 8:337-344.

**Lubeck DP**, **Pasta DJ**, Flanders SC, Henning JM. *Approaches to missing data inference: Results from CaPSURE*. Pharmacoeconomics. 1999.15;197-204.

Stier DM, Greenfield S, **Lubeck DP**, Dukes KA, Flanders SC, Henning JM, Weir J, Kaplan SH. 1999 *Quantifying comorbidity in a disease-specific cohort: the adaptation of the total illness burden index to prostate cancer*. Urology. 54:424-429.

**Mathias SD**, O'Leary MP, Henning JM, **Pasta DJ**, Fromm SR. *A comparison of patient and partner responses to a brief sexual function questionnaire*. J Urol. 1999. 162:1999-2002.

**Lubeck DP**, **Pasta DJ**, Flanders S C, Henning J M. *Approaches to missing data inference results from CaPSURE: an observational study of patients with prostate cancer*. Pharmacoeconomics. 1999 15 197-204.

**Lubeck DP**, **Pasta DJ**, Flanders S CHenning J M *Approaches to missing data inference results from CaPSURE: an observational study of patients with prostate cancer*. Pharmacoeconomics. 199915:197-204.

Litwin M S, Flanders S C, **Pasta DJ**, Stoddard M L, **Lubeck D**, PHenning J M. *Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE*. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology. 1999. 54:503-8.

Litwin M S, Flanders S C, **Pasta DJ**, Stoddard M L, **Lubeck D P**, Henning J M. *Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE*. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology. 199. 54:503-8.

## **Women's Health**

Fenster L, Quale C, Waller K, Windham GC, **Elkin EP**, Benowitz N, Swan SH. *Caffeine consumption and menstrual function*. American Journal of Epidemiology. 1999. 149:550-557.

Windham GC, **Elkin EP**, Swan SH, Waller KO, Fenster L. *Cigarette smoking and effects on menstrual function*. 1999. 93:59-65.

**Noe LL**, Becker R V 3<sup>rd</sup>, Gradishar W J, Gore M, **Trotter JP**. *The cost effectiveness of tamoxifen in the prevention of breast cancer*. Am J Manag Care. 1999. 5:S389-406.



---

### ***Methodological***

Bernhardt T, Madl A, Sheehan P, **Exuzides KA**. *Chemical fingerprinting for litigation support: a case study of effective environmental forensics*. Proceedings, Annual Meeting of the Society for Risk Analysis Atlanta, GA. 1999.

**Trotter JP**. *Patient Registries: A Scientific Complement to Product Launch*. Manag Care Interface. 1999.

**Pasta DJ**, Taylor J L, Henning J M. *Probabilistic sensitivity analysis incorporating the bootstrap: an example comparing treatments for the eradication of Helicobacter pylori*. Med Decis Making. 1999. 19:353-63.

Heinsohn P, Harney S, **Exuzides KA**. *Sporulation of the hyphomycete stachybotrys chartarum under three light conditions: bioaerosols, fungi and mycotoxins: health effects, assessment, prevention and control Chapter 3 (Microbiology)*, Edited by Johanning E, EASTERN New York Occupational and Environmental Health Center Mount Sinai School of Medicine, Department of Community Medicine. 1999.



---

## ICON LIFECYCLE SCIENCES PUBLICATIONS – 1998

---

### **Cardiovascular**

Canto J G, Rogers W J, Chandra N, French W J, Barron H V, **Frederick PD**, Maynard C. *A comparative analysis of women and men in the usage of hospital resources among payer groups: Results from the NRM1 2. Journal of Investigative Medicine.* 1998. 46:60A.

Kereiakes DL, Lincoff AM, **Miller DP**, Tcheng JE, Cabot CF, Anderson KM, Weisman HF, Califf RM, Topol EJ. *Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications.* EPILOG Trial Investigators Circulation. 1998. 97:857-864.

Sgarbossa EB, Pinski SL, Topol EJ, Califf RM, Barbagelata A, Goodman SG, Gates KB, Granger CB, **Miller DP**, Underwood DA, Wagner GS. *Acute myocardial infarction and complete bundle branch block at hospital admission: clinical characteristics and outcome in the thrombolytic era. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [ tissue-type plasminogen activator] for Occluded Coronary Arteries.* Journal of the American College of Cardiology. 1998. 31:105-110.

Asher CR, **Miller DP**, Grimm RA, Cosgrove DM 3<sup>rd</sup>, Chung MK. *Analysis of risk factors for development of atrial fibrillation early after cardiac valvular surgery.* Am J Cardiol. 1998. 82:892-5.

Kong DF, Califf RM, **Miller DP**, Moliterno DJ, White HD, Harrington RA, Tcheng JE, Lincoff AM, Hasselblad V, Topol EJ. *Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease.* Circulation. 1998. 98:2829-35.

Ellis SG, Brown KJ, Ellert R, Howell GL, **Miller DP**, Flowers NM, Ott PA, Keys T, Loop FD, Topol EJ. *Cost of cardiac care in the three years after coronary catheterization in a contained care system: critical determinants and implications.* Journal of the American College of Cardiology. 1998. 31:1306-13.

Burns M, Becker RC, Every NR, Maynard C, **Frederick PD**, Gore JM, Lambrew C, for the NRM1 Investigators. *Current in-hospital management of patients with non-ST segment elevation myocardial infarction: The National Registry of Myocardial Infarction perspective.* J Am Coll Cardiol. 1998. 31:73A.

Chung MK, Schweikert RA, Wilkoff BL, Niebauer MJ, Pinski SL, Trohman RG, Kidwell GA, Jaeger FJ, Morant VA, **Miller DP**, Tchou PJ. *Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-house monitoring and prediction of risk for significant arrhythmia complications.* Journal of the American College of Cardiology. 1998. 32:169-76.

Ghaffari S, Kereiakes DJ, Lincoff AM, Kelly TA, Timmis GC, Kleiman NS, Ferguson JJ, **Miller DP**, Califf RA, Topol EJ. *Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcomes by C7e3 gp IIb/IIIa Receptor Blockade American Journal of Cardiology.* 1998. 82:7-12.

Canto J G, Rogers W J, Chandra N, French W J, Barron H V, **Frederick PD**, Maynard C. *The influence*

---



---

*of payer status on resource utilization among hospitalized women with acute myocardial infarction in the US: Results from the NRMI 2.* Journal of Investigative Medicine. 1998. 46:64A.

### **Dermatology/Cosmetic Surgery**

**Lubeck DP.** *Measuring health-related quality of life in onychomycosis.* J American Academy of Dermatology. 1998. 38:S64-68.

### **Diagnostics/Radiology**

Walton DL, Norem CT, Schoen EJ, Ray GT, **Colby CJ.** *Second-trimester serum chorionic gonadotropin concentrations and complications and outcome of pregnancy.* N Engl J Med. 1998. 341::2033-8.

### **Gastroenterology/Digestive Diseases**

Levin TR, Schmittiel JA, Henning JM, Kunz K, Henke CJ, **Colby CJ,** Selby JV. *A cost analysis of a Helicobacter pylori eradication strategy in a large health maintenance organization.* Am J Gastroenterol. 1998. 93:743-7.

Hanauer S, BCohen R, DBecker R V 3<sup>rd</sup>, **Larson LR, Vreeland MG.** *Advances in the management of Crohn's disease: economic and clinical potential of infliximab.* Clin Ther. 1998. 20:1009-1028.

Kremer J, O'Dell J, Bulpitt K, McGuigan J, **Trotter JP,** Lefkowitz J. *Analysis of physician assessment of the patient at risk for nonsteroidal anti-inflammatory drug (NSAID) - related GI toxicity from the STAART registry database.* 62nd Annual ACR National Meeting. 1998.

Cohen RD, **Larson LR,** Roth JM. *Crohn's disease hospitalizations: Where does the money go?* Am J Gastroenterol. 1998. 93:1754.

Goldstein JL, **Larson LR,** Yamashita BD. *Diclofenac/Misoprostol vs PPI prophylaxis in the prevention of NSAID-induced complications: A cost model comparison.* American Gastroenterological Association (AGA) Conference. 1998.

**Mathias SD, Miller DP, Pasta DJ, Colwell HH,** Henning JM. *Fine tuning the extended QTWiST algorithm to compute quality days incrementally gained (QDIG).* Fifth Annual Meeting of the International Society for Quality of Life Research (ISOQOL). 1998.

Goldstein J, **Larson LR,** Yamashita B D. *Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy: clinical and economic implications of a single-tablet formulation of diclofenac/misoprostol.* Am J Manag Care. 1998. 4:687-97.

### **Infectious Disease/Immunology**

Darasieh F, Shrestha N, Pursell K, Pitrak D, Verral S, **Hasan E.** *Effect of filgastrim (r-metHuG-CSF) on impaired phagocyte respiratory burst capacity in transplant patients.* J. of Inv. Medicine. 1998. 46:pA217.



A Symbol of Excellence

---

## **Neurology/CNS**

Fillingim RB, Maixner W, Bunting S, **Silva SJ**. *Resting Blood Pressure and Thermal Pain Responses Among Females: Effects on Pain Unpleasantness but Not Pain Intensity*. International Journal of Psychophysiology. 1998. 30:313-8.

Maixner W, Fillingim R, Sigurdsson A, Kincaid S, **Silva SJ**. *Sensitivity of Patients with Painful Temporomandibular Disorders to Experimentally Evoked Pain: Evidence of Altered Temporal Summation of Pain*. Pain. 1998. 76:71-81.

Fillingim RB, Maixner W, Kincaid S, **Silva SJ**. *Sex Differences in Temporal Summation but Not Sensory-Discriminative Processing of Thermal Pain*. Pain. 1998. 75:121-7.

**Vreeland MG**. *The economic burden of migraine: The role of triptans*. Am J Manag Care. 1998. 630-2

Hughes EF, **Larson LR**. *Current considerations in the treatment of migraine: Managed care implications - Roundtable discussion*. Manag Care Interface. 1998.

Patrick DL, **Mathias SD**, **Elkin EP**, Fifer SK, Buesching DP. *Health state preferences of persons with anxiety*. International Journal of Technology Assessment in Health Care. 1998. 14:357-371.

**Trotter JP**. *Triptan use and the economic impact of migraine*. Am J Manag Care. 1998. 633-6.

## **Oncology**

Payne R, **Mathias SD**, **Pasta DJ**, Wanke L A, Williams R, Mahmoud R. *Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine*. J Clin Oncol. 1998. 16:1588-93.

Schonfeld WH, **Elkin EP**, Woltering EA, Modlin IM, Anthony L, Villa KF, Zagari M. *The cost-effectiveness of octreotide acetate in the treatment of carcinoid syndrome and VIPoma*. International Journal of Technology Assessment in Health Care. 1998. 14:514-525.

## **Psychiatry**

Miller WB, **Pasta DJ**, Dean CL. *Testing a Model of the Psychological Consequences of Abortion. The New Civil War: The Psychology, Culture, and Politics of Abortion*. 1998.

## **Respiratory/Pulmonary**

**Neil NN**, Sullivan S D, Lessler D S. *The economics of treatment for infants with respiratory distress syndrome*. Med Decis Making. 1998. 18:44-51.

Ward MM, **Lubeck DP**, Leigh JP. *Long-term health outcomes of patients with rheumatoid arthritis treated in managed care and fee-for-service practice settings*. Journal of Rheumatology. 1998. 25:641-649.



---

**Trotter JP.** *Introduction Innovations in the treatment of chronic arthritis pain: Implications for managed care.* Manag Care Interface. 1998.

Goldstein JL, Stewart D, Zabinski RA, **Larson LR.** *The economic implications of decreased patient adherence to co-prescribed diclofenac and misoprostol relative to a single-tablet formulation of diclofenac/misoprostol.* Value Health. 1998. 1:57.

### **Urology**

Litwin MS, **Lubeck DP,** Henning JM, Carroll PR. *Differences in urologist and patient assessments of health-related quality of life in men with prostate cancer: results from the CaPSURE database.* Journal of Urology. 1998. 159:1988-1992.

**Lubeck DP,** Peeples PJ, Prebil LA, **Cisternas M.** *Reduction in extent to which patients are bothered by symptoms reported in the Urge Urogenital Distress Inventory.* Quality of Life Research. 1998. 7:628.

Litwin M, **Pasta D J,** Stoddard M L, Henning J M, Carroll P R. *Epidemiological trends and financial outcomes in radical prostatectomy among Medicare beneficiaries, 1991 to 1993.* J Urol. 160:445-8.

Penson D, FLitwin M S, **Lubeck DP,** Flanders S, **Pasta DJ,** Carroll P R. *Transitions in health-related quality of life during the first nine months after diagnosis with prostate cancer.* Prostate Cancer Prostatic Dis 1. 1998:134-143.

Penson D, FLitwin M S, **Lubeck DP,** Flanders S, **Pasta DJ,** Carroll P R. *Transitions in health-related quality of life during the first nine months after diagnosis with prostate cancer.* Prostate Cancer Prostatic Dis 1. 1998:134-143.

### **Women's Health**

**Colwell HH, Mathias SD, Pasta DJ,** Henning J M, Steege J F. *A health-related quality-of-life instrument for symptomatic patients with endometriosis: a validation study.* Am J Obstet Gynecol. 1998. 179:47-55.

van den Eeden SK, Glasser M, **Mathias SD, Colwell HH, Pasta DJ,** Kunz K. *Quality of life, health care utilization, and costs among women undergoing hysterectomy in a managed-care setting.* Am J Obstet Gynecol. 1998. 178:91-100.

Waller KS, wan SH, Windham GC, Fenster L. **Elkin EP,** Lasley BL. *Use of urine biomarkers to evaluate menstrual function in healthy premenopausal women.* American Journal of Epidemiology. 1998 147 1071-1080.

### **Methodological**

**Silva SJ,** Potter L. *Controlling for group differences and counting rare events: Propensity scores with PROC CATMOD and Poisson regression with PROC GENMOD.* Sixth Annual Western Users of SAS®



Software Regional Users Group Conference. 1998.

**Pasta DJ, Cisternas M, Williamson CL.** *Estimating standard errors of treatment effects for probit models and for linear models of log-transformed variables using PROC IML.* Sixth Annual Western Users of SAS® Software Regional Users Group Conference. 1998.

**Exuzides KA, Lau.** *Rear end characteristics in U.S. traffic accidents Proceedings.* Society of Automotive Engineers International Meeting. 1998.

**Mathias SD, Bloor LE, Colwell HH, Lubeck DP, Prebil LA.** *Satisfaction with treatment: Where we are and where we should be.* Fifth Annual Symposium of Contributed Papers on Quality of Life Evaluation, Drug Information Association and Agency for Healthcare Research and Quality. 1998.



A Symbol of Excellence

---

## ICON LIFECYCLE SCIENCES PUBLICATIONS – 1997

---

### **Cardiovascular**

Klein AL, Grimm RA, Black IW, Leung DY, Chung MK, Vaughn SE, Murray RD, **Miller DP**, Arheart KL, for the Acute Investigators. *Cardioversion Guided by Transesophageal Echocardiography: The ACUTE Pilot Study*. *Annals of Internal Medicine*. 1997. 126:200-209.

Migrino RQ, Young JB, Ellis SG, White HD, Lundergran CF, **Miller DP**, Granger CB, Ross AM, Califf RMTopol EJ, for the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I Angiographic Investigators. *End-Systolic Volume Index at 90 to 180 Minutes Into Reperfusion Therapy for Acute Myocardial Infarction Is a Strong Predictor of Early and Late Mortality*. *Circulation*. 1997. 96:116-121.

Simpfendorfer C, Kottke-Marchant K, Lowrie M, Anders RJ, Burns DM, **Miller DP**, Cove CS, DeFranco ACEllis SG, Moliterno DJ, Raymond RE, Sutton JM, Topol EJ. *First Chronic Platelet Glycoprotein IIb/IIIa Integrin Blockade: A Randomized, Placebo-Controlled Pilot Study of Xemilofiban in Unstable Angina With Percutaneous Coronary Interventions*. *Circulation*. 1997. 96:76-81.

Mak KH, Moliterno DJ, Granger CB, **Miller DP**, White HD, Wilcox RG, Califf RM, Topol EJ. *Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction*. GUSTO-I Investigators. *Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries*. *J Am Coll Cardiol*. 1997. 30:171-9.

Every NR, **Parsons LS**, Fihn SD, Larson EB, Maynard C, Hallstrom AP, Martin JS, Weaver WD. *Long-term outcome in acute myocardial infarction patients admitted to hospitals with and without on-site cardiac catheterization facilities*. *Circulation*. 1997. 96:1770-5.

Every NR, **Parsons LS**, Hlatky MA, McDonald KM, Thom D, Hallstrom AP, Martin JS, Weaver WD. *The use and accuracy of state death certification of sudden cardiac deaths in high risk populations*. *American Heart Journal*. 1997. 134:1129-1132.

Chung MK, Pogwizd SM, **Miller DP**, Cain ME. *Three-dimensional mapping of the initiation of nonsustained ventricular tachycardia in the human heart*. *Circulation*. 1997. 95:2517-27.

**Trotter JP**. *Torse mide: pharmaco-economic research in the United States*. International Press Conference sponsored by Boehringer Mannheim Pharmaceuticals. 1997.

**Mathias SD**, Bates M M **Pasta DJ**, **Cisternas M**, Feeny D, Patrick DL. *Use of the Health Utilities Index with stroke patients and their caregivers*. *Stroke*. 1997. 28:888-94.

### **Diagnos tics/Radiology**

Urban N, Drescher C, Etzioni R, **Colby C**. *Use of a stochastic simulation model to identify an efficient protocol for ovarian cancer screening*. *Control Clin Trials*. 1997. 18:251-70.



---

### **Endocrinology/Maetabolic**

**Mathias SD**, Williamson C L, **Colwell HH**, **Cisternas M**, **Pasta DJ**, Stolshek B S, Patrick D L. *Assessing health-related quality-of-life and health state preference in persons with obesity: a validation study.* Qual Life Res. 1997. 6:311-22.

**Mathias SD**, **Pasta DJ**, Prebil LA, Williamson C, Stolshek B. *Quality of life during treatment with Orlistat (Xenical), Presented at North American Association for the Study of Obesity (NAASO).* North American Association for the Study of Obesity (NAASO), Cancun, Mexico, November 9-13, 1997.

### **Gastroenterology/Digestive Diseases**

Levin TR, Schmittiel JA, Kunz K, Henning JM, Henke CJ **Colby CJ**, Selby JV. *Costs of acid-related disorders to a health maintenance organization.* Am J Med. 1997. 103 520-8.

Brown S J, Lieberman D A, Germeny B A, Fan Y C, Wilson D M, **Pasta DJ**. *Educational video game for juvenile diabetes: results of a controlled trial.* Med Inform (Lond). 1997. 22:77-89.

### **Hematology**

Francis CW, Pellegrini V, Marder S, Totterman S, Pleil AM, **Reinhard SP**, **Trotter JP**. *A prospective clinical and economic comparison of warfarin and dalteparin in prevention of deep vein thrombosis following total hip replacement.* Sixteenth Congress of the International Society of Thrombosis and Haemostasis. 1997.

Pleil AM, Francis CW, **Reinhard SP**, **Trotter JP**. *A prospective, pharmacoeconomic evaluation of fragmin in total hip replacement surgery.* 144th Annual Meeting of the American Pharmaceutical Association. 1997.

### **Infectious Disease/Immunology**

Leigh JP, **Lubeck DP**, Farnham P, Fries JF. *Absenteeism and HIV infection.* Applied Economics Letters. 1997. 4:275-280.

**Lubeck DP**, Fries JF. *Assessment of quality of life in early stage HIV-infected persons: data from the AIDS Time Oriented Health Outcome Study (ATHOS).* Quality of Life Research. 1997. 6:494-506.

### **Nephrology**

Selby JV, Ray GT, Zhang D, **Colby CJ**. *Excess costs of medical care for patients with diabetes in a managed care population.* Diabetes Care. 1997. 20:1396-402.



A Symbol of Excellence

---

### **Neurology/CNS (Mental Health)**

Schonfeld WH, Verboncoeur CJ, Fifer SK, Lipschutz RC, **Lubeck DP**. *Functioning and well-being of patients with unrecognized anxiety disorders and major depressive disorder*. Journal of Affective Disorders. 1997. 43:105-119.

### **Oncology**

Gann PH, Chatterton RT, Vogelsong K, Dupuis J, **Ellman A**. *Mitogenic growth factors in breast fluid obtained from healthy women: evaluation of biological and extraneous sources of variability*. Cancer Epidemiol Biomarkers Prev. 1997. 6:421-28.

### **Psychiatry**

Darby J K, **Pasta DJ**, Elfand L, Dabiri L, Clark L, Herbert J. *Risperidone dose and blood level variability: accumulation effects and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting*. J Clin Psychopharmacol. 1997. 17:478-84.

### **Rheumatology/Arthritis**

Clarke AE, Zowall H, Levington C, Sibley J, Shiroky J, **Lubeck DP**, Esdaile JM. *The direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a twelve-year study*. Journal of Rheumatology. 1997. 24:1051-1060.

### **Urology**

Prebil LA, **Mathias SD**, **Lubeck DP**. *Responsiveness of quality-of-life questionnaires in clinically stable patients: Results from three validation studies American Public Health Association's 125th Annual Meeting*. 1997.

### **Methodological**

Wall DS, **Noe LL**, Abel SR, Hardwick LL, Plesek SR. *A resource use comparison of Monovial® with traditional methods of preparing extemporaneous small-volume intravenous infusions*. Hosp Pharm. 1997. 32:1647-56.

Prebil LA, **Mathias SD**, **Pasta DJ**. *The relationship between patients' self-perceived general health and treatment satisfaction in randomized clinical trials – preliminary findings 4th Annual Symposium of Contributed Papers on Quality-of-Life Evaluation, Charleston, South Carolina*. 1997.

Potter L, **Pasta DJ**. *The sum of squares are all the same - how can the LSMEANS be so different?* Fifth Annual Western Users of SAS® Software Regional Users Group Conference. 1997.

Urban N, Drescher C, Etzioni R, **Colby C**. *Use of a stochastic simulation model to identify an efficient protocol for ovarian cancer screening*. Control Clin Trials. 1997. 18:251-70.



A Symbol of Excellence

---

## ICON LIFECYCLE SCIENCES PUBLICATIONS – 1996

---

### **Cardiovascular**

Every NR, **Parsons LS**, Hlatky M, Martin JS, Weaver WD, for the Myocardial Infarction Triage and Intervention Investigators. *A Comparison of Thrombolytic Therapy with Primary Coronary Angioplasty for Acute Myocardial Infarction*. New England Journal of Medicine. 1996. 335:1253-60.

Heaton AH, **Trotter JP**. *A pharmacoeconomic assessment of torsemide in the treatment of congestive heart failure*. Am J Manag Care. 1996.

Cohen GI, Duffy CI, Klein AL, **Miller DP**, Cosgrove DM, Stewart WJ. *Color Doppler and two-dimensional echocardiographic determination of the mechanism of aortic regurgitation with surgical correlation*. Journal of American Society of Echocardiogram. 1996. 9:508-515.

Wang CW, Steinhubl SR, Castellani WJ, Van Lente F, **Miller DP**, James KB, Young JB. *Inability of serum myocyte death markers to predict acute cardiac allograft rejection*. Transplantation. 1996. 62:1938-41.

Klein AL, Murray RD, Black IW, Chandra S, Grimm RA, D'Sa AP, Leung DYC, **Miller DP**, Morehead AJ, Vaughn SE, Thomas JD. *Integrated Backscatter for Quantification of Left Atrial Spontaneous Echo Contrast*. Journal of the American College of Cardiology. 1996. 28:222-223.

Fahy GJ, Pinski SL **Miller DP**, McCabe N, Pye C, Walsh MJ, Robinson K. *Natural history of isolated bundle branch block American Journal of Cardiology*. 1996. 77:1185-90.

Heaton AH, Bryant J, Berman BN, **Trotter JP**. *Pharmacoeconomic comparison of loop diuretics in the treatment of congestive heart failure*. Med Interface. 1996. 9:101-7.

**Trotter JP**. *The pharmacoeconomics of congestive heart failure National Managed Healthcare*. Congress West. 1996.

### **Gastroenterology/Digestive Diseases**

**Mathias SD**, Castell DO, **Elkin EP**, Matosian ML. *Health-related quality of life of patients with acute erosive reflux esophagitis*. Digestive Disease and Sciences. 1996. 41:2123-2129.

Goldstein JL, **Larson LR**, Yamashita BD, Boyd MS. *Management of NSAID-induced gastropathy: An economic decision analysis*. Clin Ther. 1996. 19:1497-509.

### **Infectious Disease/Immunology**

O'Dell MW, Hubert HB, **Lubeck DP**, O'Driscoll P. *Physical disability in a cohort of persons with AIDS*. AIDS. 1996. 10:667-673.



---

## **Neurology/CNS**

Kim JH, **Ellman A**, Juraska JM. *A re-examination of sex differences in axon density and number in the splenium of the rat corpus callosum*. Brain Res. 1996. 740:47-56.

Chatterton RT Jr., Vogelsong KM, Lu YC, **Ellman A**, Hudgens GA. *Salivary alpha-amylase as a measure of endogenous adrenergic activity*. Clin Physio. 1996. 16:433-48.

## **Psychiatry**

Miller WB, **Pasta DJ**. *Couple disagreement: effects on the formation and implementation of fertility decisions*. Pers Relatsh. 1996. 3:307-36.

Larson LR, Ortmeier B, **Trotter JP**. *Pharmacoeconomics in behavioral health care*. Behavioral Health Management. 1996. 15:8-11

Miller WB, **Pasta DJ**. *The relative influence of husbands and wives on the choice and use of oral contraception, a diaphragm, and condoms*. J of Appl Social Psychol. 26:1749-74.

## **Rheumatology/Arthritis**

**Noe LL**, Heaton A, Berman-Schneider B, Bryant J, Simons R, Haim M, **Trotter J**. *The treatment of rheumatoid arthritis (RA) in managed care: A pharmacoeconomic assessment*. Arthritis Rheum. 1996. 39:S272.

## **Urology**

**Lubeck DP**, Litwin MS, Henning JM, Stier D, Mazonson P, Fisk R, Carroll PR. *The CaPSURE database: a methodology for clinical practice and research in prostate cancer*. Urology. 1996:48.

## **Methodological**

Wall DS, **Noe LL**, Hardwick LL, Plesek SR, Abel SR. *A resource use comparison of Monovial® with traditional methods of preparing small-volume intravenous solutions*. 31st Annual ASHP Midyear Clinical Meeting. 1996.

**Trotter JP**. *Conducting naturalistic pharmacoeconomic research in managed care*. Pharmacoeconomics and Quality-of-Life Symposium. 1996.

**Pasta DJ**, Potter L. *Exploratory variable clustering for integrating analyses*. Fourth Annual Western Users of SAS® Software Regional Users Group Conference. 1996.

**Mathias SD**, **Cisternas M**, Williamson CL, Prebil LA, **Pasta DJ**. *Healing "messy" data from quality-of-life questionnaires*. Presented at the Third Annual Meeting of the International Society for Quality of Life Research, Manila, Phillippines. 1996.



**Pasta DJ.** *The intraclass correlation: What is it and why do we care?* Fourth Annual Western Users SAS® Software Regional Users Group Conference. 1996.



A Symbol of Excellence

---

## ICON LIFECYCLE SCIENCES PUBLICATIONS – 1995

---

### **Cardiovascular**

**Trotter JP.** *Cost-effective decision model for congestive heart failure.* Boehringer-Mannheim symposium at the Annual Meeting for the Academy of Managed Care Pharmacy. 1995.

**Trotter JP.** *Decision model for the cost-effective treatment of congestive heart failure.* Boehringer-Mannheim symposium at the Annual Meeting for the Academy of Managed Care Pharmacy. 1995.

Ellis SG, **Miller DP**, Brown KJ, Omoigui N, Howell GL, Grierson J, Kutner M, Topol EJ. *In-Hospital cost of percutaneous coronary revascularization: critical determinants and implications.* *Circulation.* 1995. 92:741-7.

Weiner DA, Ryan TJ, **Parsons L**, Fisher LD, Chaitman BR, Sheffield LT, Tristani FE. *Long-term Prognostic Value of Exercise Testing in Men and Women from the Coronary Artery Surgery Study (CASS) Registry.* *American Journal of Cardiology.* 1995. 75:865-870.

Weaver WD, **Parsons L**, and Every N for the MITI Project Investigators. *Primary Coronary Angioplasty in Hospitals With and Without Surgery Backup.* *The Journal of Invasive Cardiology.* 1995. 7:34F-39F.

Weiner DA, Ryan TJ, **Parsons L**, Fisher LD, Chaitman BR, Sheffield L, Tristani FE. *Significance of Silent Myocardial Ischemia During Exercise Testing in Women: A Report from the Coronary Artery Surgery Study (CASS) Registry.* *American Heart Journal.* 1995. 129:465-470.

Heric B, Lytle BW, **Miller DP**, Rosenkranz ER, Lever HM, Cosgrove DM. *Surgical management of hypertrophic obstructive cardiomyopathy: Early and late results.* *Journal of Thoracic and Cardiovascular Surgery.* 1995. 110:195-206.

Cosgrove DM, Lytle BW, Taylor PC, Camacho MT, Stewart RW, McCarthy PM, **Miller DM**, Piedmonte MR, Loop FD. *The Carpentier-Edwards pericardial aortic valve: Ten-year results.* *Journal of Thoracic and Cardiovascular Surgery.* 1995. 110:651-662.

**Trotter JP.** *The pharmacoeconomics of congestive heart failure.* Academy of Managed Care Pharmacy. 1995.

**Trotter JP.** *The pharmacoeconomics of congestive heart failure.* Cardiovascular Disease Management seminar. 1995.

### **Dermatology/Cosmetic Surgery**

Holman A R, Brumer S, Ware W H, **Pasta DJ.** *The impact of interpersonal support on patient satisfaction with orthognathic surgery.* *J Oral Maxillofac Surg.* 1995. 53, 1289-97: discussion 1297-9

---

ICON Clinical Research  
Lifecycle Sciences Group  
(415) 741-2101

[Deborah.Lubeck@iconplc.com](mailto:Deborah.Lubeck@iconplc.com)



---

### ***Infectious Disease/Immunology***

**Lubeck DP**, Shi H, Bloch DA, Fries JF. *Clinical correlates of quality of life among males with HIV-Infection*. Quality of Life Research. 1995. 4:456-457.

Bennett CL, **Lubeck DP**, McShane DJ, Mathews JK, Lipil WH. *Costs of terminal care for persons with AIDS*. AIDS Patient Care. 1995. 9:7-9.

Leigh JP, **Lubeck DP**, Farnham PG, Fries JF. *Hours at work and employment status among HIV patients*. AIDS. 1995. 9:81-88.

Leigh JP, **Lubeck DP**, Farmhand P Fries. *Potential and actual workdays lost among patients with HIV*. Journal of Acquired Immune Deficiency Syndromes. 1995. 8:392-398.

O'Dell MW, **Lubeck DP**, Matson S. *Validity of the Karnofsky performance status in an HIV-infected sample*. Journal of Acquired Immune Deficiency Syndromes. 1995. 10:350-357.

Ewert DP, Westman S, **Frederick PD**, Waterman SH. *Measles reporting completeness during a community-wide epidemic in inner-city*. Los Angeles Public Health Rep. 1995. 110:161-5.

### ***Neurology/CNS***

**Reinhard SP**, Trotter JP, Larson LR. *A pharmacoeconomic comparison of narcotic and non-narcotic analgesics in abdominal surgery*. P & T. 1995.

### ***Neurology/CNS (Mental Health)***

Kuppermann M, **Lubeck DP**, Mazonson PD, Patrick DL, Stewart AL, Buesching DP, Fifer SK. *Sleep problems and their correlates in a working population*. Journal of General Internal Medicine. 1995. 10:25-32.

### ***Psychiatry***

Miller WB, **Pasta DJ**. *Behavioral intentions: Which ones predict fertility behavior in married couples?* Journal of Applied Social Psychology. 1995. 25:530-555.

Darby J K, **Pasta DJ**, , Dabiri L, Clark L, Mosbacher D. *Haloperidol dose and blood level variability: toxicity and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting*. J Clin Psychopharmacol. 1995. 15:334-40.

Miller WB, **Pasta DJ**. *How does childbearing affect fertility motivations and desires?* Soc Biol. 1995. 42:185-98.

### ***Rheumatology/Arthritis***

**Lubeck DP**. *The economic impact of arthritis*. Arthritis Care and Research. 1995. 8:306-324.



A Symbol of Excellence

---

### **Urology**

Butler B, Novick A, **Miller DP**, Campbell SA, Licht MR. *Management of small unilateral renal cell carcinomas: Radical versus nephron-sparing surgery.* The Journal of Urology 1995. 45:34-40.

Steinbach F, Novick A, Zincke H, **Miller DP**, Williams RD, Lund G, Skinner DG, Esrig D, Richie JP, deKernion JB, Marshall F, Marsh CL. *Treatment of renal cell carcinoma in von Hippel Lindau disease: a multicenter study.* The Journal of Urology. 1995. 153:1812-6.

### **Women's Health**

**Trotter JP**, Glasser MH. *Alternative approaches to hysterectomy: clinical and economic implications for managed care Med Interface.* 1995. 8:123-9.

Carter JC, **Trotter JP**. *GnRH analogs in the treatment of endometriosis: clinical and economic considerations.* Female Patient.1995. 20:13-20.

Chapko KM, Weaver MR, Chapko MK, **Pasta DJ**, , Adamson GD. *Stability of in vitro fertilization-embryo transfer success rates from the 1989, 1990, and 1991 Clinic-Specific Outcome Assessments.* Fertil Steril. 1995 64:757-63.

### **Methodological**

**Exuzides KA**, Peck R. *A simulation study on selection bias in quasi-experiments.* Research and Development of the California Department of Motor Vehicles. 1995.

**Trotter JP**. *The ABCs of cost-effectiveness.* Mater Manag Health Care. 1995. 4:18-20, 22, 24.

**Larson LR, Trotter JP**. *The continuing evolution of pharmacoeconomics.* Product Management Today. 1995 5:7-10.

**Trotter JP**. *The Quest for Cost-Effectiveness in Health Care: Achieving Clinical Excellence While Controlling Costs.* American Hospital Publishing Co, division of the American Hospital Association. 1995.

**Exuzides KA**. *California births to remain relatively flat to the year 2005.* California Department of Finance. 1995.

### **Cardiovascular**

Manapat AE, McCarthy PM, Lytle BW, Taylor PC, Loop PC, Stewart RW, Rosenkranz ER, Sapp SK, **Miller DP**, Cosgrove DM. *Gastroepiploic and inferior epigastric arteries for coronary artery bypass: Early results and evolving applications.* Circulation. 1995. 90:1144-7.



---

### **Hematology**

Kosnett MJ, Becker CE, Osterloh JD, Kelly TJ **Pasta DJ**. *Factors influencing bone lead concentration in a suburban community assessed by noninvasive K x-ray fluorescence*. JAMA. 1995. 271(3):197-203.

### **Infectious Disease/Immunology**

**Noe LL**, Pribble J, Levy H, Opal SM, Balk RA, Fisher CJ, Dhainaut JF, Bloom BS, Barriere SL, Gordon. GSIL-1ra Sepsis Syndrome Study Group 1994 *A comparison of hospital resource efficiency in patients with sepsis treated with anakinra (recombinant human interleukin-1 receptor antagonist) or placebo*. Intensive Care Med. 1995. 20:S20.



A Symbol of Excellence

---

## ICON LIFECYCLE SCIENCES PUBLICATIONS – 1994

---

### ***Infectious Disease/Immunology***

**Noe LL**, Pribble J, Barriere SL, Drummond MF, Van Hout BA, Bloom BS, Levy H, Opal SM, Balk RA, Johnson SB, Dhainaut JFA, Gordon G. SrhIL-1ra Sepsis Syndrome Study Group 1994 *An analysis of hospital length of stay in a double-blind, placebo-controlled clinical trial of recombinant human interleukin-1 receptor antagonist (anakinra) in the treatment of patients with sepsis syndrome.* Pharmacotherapy. 1995. 14:371.1994

Horsburgh CR, Chin DP, Yajko DM, Hopewell PC, Nassos PS **Elkin EP**, Hadley WK, Stone EN, Simon EM, Gonzalez P, Ostroff S, Reingold AL. *Environmental risk factors for acquisition of Mycobacterium avium complex in persons with human immunodeficiency virus infection.* Journal of Infectious Diseases. 1994. 170:362-367.

Chin DP, Reingold AL, Horsburgh CR, Yajko DM, Hadley WK, **Elkin EP**, Stone EN, Simon EM, Gonzalez PC, Ostroff SM, Jacobson MA, Hopewell PC. *Predicting Mycobacterium avium complex bacteremia in patients infected with the human immunodeficiency virus: A prospectively validated model.* Clinical Infectious Diseases. 1994. 19:668-674.

**Noe LL**, Pribble J, Barriere S, Fisher C, Dhainaut JF, Opal S, Gordon G. IL-1ra Phase III Sepsis Syndrome Study Group. *The impact of interleukin-1 receptor antagonist (IL-1ra) on the hospital and ICU length of stay of patients with sepsis syndrome.* Crit Care Med. 1994. 22:A117.

Ewert DP, **Frederick PD**, Run GH, Mascola L. *The reporting efficiency of measles by hospitals in Los Angeles County, 1986 and 1989.* Am J Public Health. 1994. 84:868-9.

### ***Neurology/CNS (Mental Health)***

**Lubeck DP**, Fries JF. *Changes in health status after one year for persons at-risk for and with HIV infection.* Psychology and Health. 1994. 9:79-92

**Lubeck DP**, Mazonson PD, Bowe T. *Potential effect of tacrine on expenditures for Alzheimer's disease.* Medical Interface. 1994. 7:130-138

**Mathias SD**, Fifer S K, Mazonson P D, **Lubeck DP**, Buesching D P, Patrick D L. *Necessary but not sufficient: the effect of screening and feedback on outcomes of primary care patients with untreated anxiety.* J Gen Intern Med. 1994. 9 606-15.

### ***Oncology***

**Trotter JP**. *Introduction GnRH agonists for the treatment of advanced prostate cancer: Managed care implications.* Med Interface. 1994.



A Symbol of Excellence

---

### **Psychiatry**

Fifer SK, **Mathias SD**, Patrick DL, Mazonson PD, **Lubeck DP**, Buesching DP. *Untreated anxiety among adult primary care patients in a health maintenance organization*. Archives of General Psychiatry. 1994. 51:740-750.

Dabiri LM, **Pasta DJ**, Darby JK, Mosbacher D. Effectiveness of vitamin E for treatment of long-term tardive dyskinesia. Am J Psychiatry. 1994.151(6):925-6.

Miller WB, **Pasta DJ**. *The psychology of child timing: a measurement instrument and a model*. J of Applied Social Psychol. 1994. 24(3):218-50.

### **Rheumatology/Arthritis**

Carlin B, **Noe LL**, Lookabaugh J, Witt K, Campion G, Gordon G. *Quality of life in active rheumatoid arthritis (RA) patients receiving recombinant human interleukin-1 receptor antagonist (rhIL-1ra, Anakinra)*. Arthritis Rheum. 1994. 37:S249.

### **Urology**

Steinbach F, Stockle M, Griesinger A, Storkel S, Stein R, **Miller DP**, Hohenfellner R. *Multifocal renal cell tumors: A retrospective analysis of 56 patients treated with radical nephrectomy*. Urology. 1994. 152:1393-6.

### **Women's Health**

**Trotter JP**, Glasser M, Hall B, et al. *GnRH agonists for the treatment of endometriosis: Implications for managed care - Roundtable discussion*. Med Interface Suppl. 1994:15-38.

Adamson GD **Pasta DJ**. *Is laparoscopic treatment of endometriosis better?* Am J Obstet Gynecol. 1994. 170(1 pt 1):255.

Adamson GD, **Pasta DJ**. *Surgical treatment of endometriosis-associated infertility: meta-analysis compared with survival analysis*. Am J Obstet Gynecol. 1994. 171(6):1488-505.

### **Methodological**

Ranz TT, **Reinhart SP**, Kelly PM. *Nursing labor associated with the administration of oral medications in long-term care: A prospective, observational study*. American Society of Consultant Pharmacists' Annual Meeting. 1994:10.

**Lubeck DP**. *Primer: quality of life assessments*. Journal of Clinical Outcomes Management. 1994.1:39-40.



A Symbol of Excellence

---

## ICON LIFECYCLE SCIENCES PUBLICATIONS – 1993

---

### **Cardiovascular**

Fix J, Isada L, Cosgrove D, **Miller DP**, Savage R, Blum J, Stewart W. *Do patients with less than 'echo-perfect' results from mitral valve repair by intraoperative echocardiography have different outcome?* Circulation. 1993. 88:1139-48.

### **Dermatology/Cosmetic Surgery**

**Lubeck DP**, Patrick DL, McNulty P, Fifer SK, Birnbaum J. *Quality of life of persons with onychomycosis.* Quality of Life Research. 1993 2:341-348.

Colwell JC, Foreman M, **Trotter JP**. *A comparison of the efficacy and cost-effectiveness of two methods of managing pressure ulcers.* Decubitus. 1993. 6:28-36.

### **Infectious Disease/Immunology**

**Lubeck DP**, Fries JF. *Health status among persons infected with human immunodeficiency virus: A community-based study.* Medical Care. 1993. 31:269-276.

Lenker S-L, **Lubeck DP**, Vosler A. *Planning community-wide services for persons with HIV infection in an area of moderate incidence.* Public Health Reports. 1993. 108:285-293.

**Lubeck DP**, Bennett CL, Mazonson PD, Fifer SK, Fries JF. *Quality of life and health service use among HIV-infected patients with chronic diarrhea.* Journal of Acquired Immune Deficiency Syndromes. 1993. 6:478-484.

**Lubeck DP**, Nobunaga AI, Williams CA, O'Dell MW 1993 *Rehabilitation of selected non-neurologic HIV disability.* Physical Medicine and Rehabilitation: State of the Art Reviews 7 S131-S153.

**Reinhart SP**, **Trotter JP**. *An economic assessment of ofloxacin.* Drugs. 1993. 45:465-466.

Eberhart-Phillips JE, **Frederick PD**, Baron RC, Mascola L. *Measles in pregnancy: a descriptive study of 58 cases.* Obstet Gynecol. 1993. 82 797-801.

**Lubeck DP**, Nobunaga AI, Williams CA, O'Dell MW. *Rehabilitation of selected non-neurologic HIV disability.* O'Dell MW (ed) Physical Medicine and Rehabilitation. 1993. 7:S131-S153.

### **Neurology/CNS**

**Trotter JP**, **Reinhart SP**, Katz R, Glazier H S. *Economic assessment of ketorolac versus narcotic analgesics in postoperative pain management.* Clin Ther. 1993. 15:938-48.



A Symbol of Excellence

---

### **Psychiatry**

Miller WB, Shain RN, **Pasta DJ**. *A model of pre-sterilization ambivalence and post-sterilization regret in married couples*. *Advances in Population*. 1993. 1:173-206.

Miller WB, **Pasta DJ**. *Motivational and non-motivational determinants of child-number desires*. *Population and Environment*. 1993. 15:113-38.

### **Respiratory/Pulmonary**

**Trotter JP**, Glazier HS, Larson LR, Thompson KA, Giles TD. *The treatment of allergic rhinitis: An economic analysis*. *Med Interface*. 1993.

### **Women's Health**

Eskenazi B, Guendelamn S, **Elkin EP**. *A preliminary study of reproductive outcomes of female maquiladora workers in Tijuana, Mexico*. *American Journal of Industrial Medicine*. 1993. 24:667-676.

Eskenazi B, Fenster L, Sidney S, **Elkin EP**. *Fetal growth retardation in infants of multiparous and nulliparous women with preclampsia*. *American Journal of Obstetrics and Gynecology*, 1993 169:1112-1118.

Adamson GD, Hurd SJ, **Pasta DJ**, Rodriquez BD. *Laparoscopic endometriosis treatment: is it better?* *Fertil Steril*. 1993. 59(1) 35-44.

### **Methodological**

**Exuzides KA**, Peck R. *An application of two stage least squares in quasi-experiments*. San Francisco. 1993.

**Trotter JP**. *The evolution of health economics*. *Product Management Today*. 1993.

**Exuzides KA**, Marsh W. *Using SAS to estimate treatment effects for the mature driver program*. *Proceedings, SAS Institute Meeting*. 1993.

Lepkowski JM, **Miller DP**, Kalton G, Singh R. *Imputation for wave nonresponse in the SIPP*. *Proceedings: Symposium 1992, Design and analysis of longitudinal survey Statistics Canada*. 1993. 99-109.



A Symbol of Excellence

---

## ICON LIFECYCLE SCIENCES PUBLICATIONS – 1992

---

### **Cardiovascular**

Bell MR, Gersh BJ, Schaff HV, Holmes DR, Fisher LD, Alderman EL, Myers WO, **Parsons LS**, Reeder GS, the investigators of the Coronary Artery Surgery Study. *Effect of Completeness of evascularization on Long-term Outcome in Patients with Three-vessel Disease Undergoing Coronary Artery Bypass Surgery*. *Circulation*. 1992. 86:446-457.

### **Infectious Disease/Immunology**

**Lubeck DP**, Fries JF. *Changes in quality of life among persons with HIV infection*. *Quality of Life Research*. 1992. 1:359-366.

Enguidanos R, Mascola L, **Frederick P**. *A survey of hospital infection control policies and employee measles cases during Los Angeles County's measles epidemic, 1987 to 1989*. *Am J Infect Control*. 1992.

Ewert D, Westmann S, **Frederick P**, Waterman S. *Measles Reporting: Reflection or Reality, Los Angeles County Department of Health Services, Immunization Demonstration Project*. American Public Health Association, 120th Annual Meeting. 1992.

Lee SH, Ewert DP, **Frederick PD**, Mascola L. *Resurgence of congenital rubella syndrome in the 1990s. Report on missed opportunities and failed prevention policies among women of childbearing age*. *JAMA*. 1992. 267:2616-20.

### **Women's Health**

Adamson GD, Subak LL, **Pasta DJ**, Hurd S, Jvon Franque O, Rodriquez BD. *Comparison of CO2 laser laparoscopy with laparotomy for treatment of endometriomata*. *Fertil Steril*. 1992. 57(5):965-7.

### **Methodological**

**Miller DP**, Kalton G, Lepkowski J. *Estimating Duration of Food Stamp Spells from the SIPP*. *ASA Proceedings of Survey Research Methods Section*. 1992. 560-565.

**Reinhart SP**, **Trotter JP**. *Incorporating economic analysis into clinical trials*. *Applied Clinical Trials*.

**Reinhart SP**. *Integrating cost effectiveness with quality improvement*. *Quest for Quality and Productivity in Health Services Annual conference*. 1992.

**Trotter JP**. *Effective product marketing with efficient use of outcomes research data*. *Seminar on Outcomes Research*. 1992.



A Symbol of Excellence

---

## ICON LIFECYCLE SCIENCES PUBLICATIONS – 1991

---

### **Cardiovascular**

Weiner DA, Ryan TJ, **Parsons L**, Fisher LD, Chaitman BR, Sheffield LT, Tristani FE. *Prevalence and Prognostic Significance of Silent and Symptomatic Ischemia after Coronary Bypass Surgery: A Report from the Coronary Artery Surgery Study (CASS) Randomized Population*. Journal of the American College of Cardiology. 1991.18:343-348.

Weiner DA, Ryan TJ, **Parsons L**, Fisher LD, Chaitman BR, Sheffield LT, Tristani FE. *Significance of Silent Myocardial Ischemia During Exercise Testing in Patients with Diabetes Mellitus: A Report from the Coronary Artery Surgery Study (Cass)*. Registry American Journal of Cardiology. 1991. 68:729-734.

### **Psychiatry**

Miller WB, Shain RN, **Pasta DJ**. *The pre- and post-sterilization predictors of post-sterilization regret in husbands and wives*. J Nerv Ment Dis. 1991. 179(10) 602-8.

Miller WB, Shain RN, **Pasta DJ**. *The predictors of post-sterilization regret in married women*. J of Applied Social Psychol. 1991. 21:1083-110.

Miller WB, Shain RN, **Pasta DJ**. *Tubal sterilization or vasectomy: how do married couples make the choice?* Fertil Steril. 1991. 56(2):278-84.

### **Rheumatology/Arthritis**

**Lubeck DP**. *Health care economics and policy*. Current Opinion in Rheumatology. 1991. 3:286-290.

### **Methodological**

**Exuzides KA**, Johnson W. *Estimation procedures for the covariance of spatial data: technical report*. University of California. 1991.

---

ICON Clinical Research  
Lifecycle Sciences Group  
(415) 741-2101

[Deborah.Lubeck@iconplc.com](mailto:Deborah.Lubeck@iconplc.com)



A Symbol of Excellence

---

## ICON LIFECYCLE SCIENCES PUBLICATIONS – 1990

---

### ***Infectious Disease/Immunology.***

Marbella A, **Frederick P**, Alexander C, Waterman S. *Epidemic Measles In Los Angeles County.* American Public Health Association, 118th Annual Meeting. 1990.

### ***Psychiatry***

Miller WB, Shain RN, **Pasta DJ.** *The nature and dynamics of post-sterilization regret in married women.* J of Applied Social Psychol. 1990. 20:506-30.



A Symbol of Excellence

---

## ICON LIFECYCLE SCIENCES PUBLICATIONS – 1989

---

### ***Infectious Disease/Immunology***

Lentini G, Heseltine P, Amling J, Evashwick E, Smith E, Waterman S, **Frederick P**, Dales L. *Measles Los Angeles County, California MMWR*. 1989. 138:49-57

### ***Psychiatry***

Miller WB, Shain RN, **Pasta DJ**. *The sterilization decision in a U.S. sample*. Choosing a Contraceptive: Factors in Method Choice in Asia and the United States. 1989.

### ***Methodological***

Rock D, **Exuzides KA**. *Robust estimation for variance components*. University of California. 1989.



A Symbol of Excellence

---

## ICON LIFECYCLE SCIENCES PUBLICATIONS – 1988

---

### ***Infectious Disease/Immunology***

Farizo K, Sterh-Green P, Markowitz L, **Frederick P.** *Missed Opportunities for Measles Vaccination in a Public Pediatric Clinic.* EIS Conference, 1988.

Farizo K, Sterh-Green P, Markowitz L, **Frederick P.** *Vaccination Levels and Missed Opportunities for Measles Vaccination in a Public Pediatric Clinic.* Los Angeles, 1988. EIS Conference. 1988.

### ***Psychiatry***

Miller WB, **Pasta DJ.** *A model of fertility motivations, desires, and expectations early in women's reproductive careers.* Soc Biol. 1988. 35(3-4):236-50.

### ***Methodological***

Weiss BP, **Frederick P.** *Use of an Active Disease Surveillance System to Obtain Reports of Drowning/Near Drowning in Los Angeles.* American Public Health Association, 116th Annual Meeting. 1988.



A Symbol of Excellence

---

## ICON LIFECYCLE SCIENCES PUBLICATIONS – 1986

---

### ***Methodological***

**Exuzides, KA.** *Asymptotic results in probability and Brownian motion.* University of Patras, Greece. 1986.



A Symbol of Excellence

---

## ICON LIFECYCLE SCIENCES PUBLICATIONS – 1984

---

### ***Infectious Disease/Immunology***

**Frederick P**, Habel L, Agee BA. *Acute Illnesses in Child Care: A Prevalence Survey in Los Angeles County Symposium on Infectious Diseases in Day Care: Management and Prevention, Minneapolis, Minnesota. 1984.*



---

## ICON LIFECYCLE SCIENCES PUBLICATIONS – 1974

---

### ***Methodological***

Shorter FC, **Pasta DJ**. *Computational Methods for Population Projection: With Particular Reference to Development Planning*. 1974.